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Introdução: A presente agenda global de saúde para o VIH/SIDA visa mobilizar os países de 
todo o mundo para enfrentar as principais lacunas na resposta ao VIH. A ONUSIDA 
estabeleceu metas ambiciosas para o tratamento do VIH para serem atingidas até 2020. A OMS 
recomenda que abordagens baseadas na evidência e estratégias inovadoras, incluindo a 
profilaxia pré-exposição (PrEP) e o autoteste de VIH, façam parte das respostas nacionais à 
epidemia de HIV. Este compromisso global sem precedentes foi lançado após uma grave crise 
financeira global, que forçou muitos países a reduzir a despesa em saúde. Este estudo teve como 
objetivo analisar os potenciais efeitos desses constrangimentos financeiros na resposta e 
políticas nacionais para o VIH em Portugal, no contexto de outros países do sul da Europa que 
também receberam programas de assistência financeira. 
Métodos: Para os objetivos deste estudo, foram realizadas quatro análises, utilizando diferentes 
abordagens metodológicas: a) Foi utilizado um modelo hierárquico de regressão de Poisson 
com efeitos aleatórios para analisar a relação entre o tempo de internamento  e  variáveis do 
doente, dos cuidados de saúde e do contexto, utilizando dados nacionais de 20,361 
internamentos ocorridos entre 2009 e 2014 em 41 hospitais públicos em Portugal; b) Para o 
período 2009-2018, foram analisados os resultados dos programas de prevenção do VIH em 
Portugal: apoio financeiro a organizações privadas sem fins lucrativos, programa de troca de 
seringas, teste rápido de VIH e distribuição de materiais preventivos; c) Para o período 2005-
2017, foram analisados os dados de vigilância de do VIH/SIDA em Portugal, usando análise 
descritiva e modelos de regressão linear para testar tendências nos novos diagnósticos de VIH 
e SIDA e diagnósticos tardios de VIH; d) Foram examinados e comparados um conjunto de 
indicadores de VIH no Chipre, Grécia, Portugal e Espanha, países que receberam assistência 
económica da União Europeia durante a crise financeira. 
Resultados: Este estudo constatou que o tempo de internamento dos doentes com VIH/SIDA 
entre 2010 e 2014 nos hospitais públicos portugueses foi significativamente menor em 
comparação com 2009, e que diversas variáveis, incluindo sexo feminino, internamento 
urgente, mortalidade hospitalar, pneumonia pneumocystis, hepatite C, e o rácio de liquidez do 
hospital contribuiu para a diminuição do tempo de tempo de internamento dos doentes com 
VIH/SIDA entre 2009 e 2014. Este estudo também mostrou que, apesar dos cortes transitórios 
de despesa em 2012-13, o Programa Nacional para a Infecção VIH e SIDA conseguiu melhorar 
a sua eficiência e manter as suas actividades principais, graças à priorização de gastos na 
expansão do teste de VIH e a um forte envolvimento com organizações da sociedade civil. A 
análise das tendências do VIH entre 2005 e 2017 mostrou uma redução significativa das novas 
infecções em todos os grupos, excepto nos homens que têm sexo com homens (HSH), onde foi 
observada uma tendência de aumento não significativa. O diagnóstico tardio ainda é comum 
em todos os grupos de transmissão, excepto nos HSH, enquanto a aquisição de VIH no 
estrangeiro é relevante entre pessoas nascidas fora de Portugal, excepto entre utilizadores de 
drogas. A análise comparativa com outros três países do sul da Europa que receberam 
assistência económica mostra que Portugal é o único país que implementou PrEP e autoteste 
de VIH. Portugal atingiu as metas 90-90-90 da ONUSIDA para o tratamento do VIH em 2017. 
Conclusão: Os resultados deste estudo mostram que os constrangimentos financeiros com que 
Portugal se defrontou não prejudicaram o progresso do país em relação à eliminação da SIDA 
até 2030, tornando Portugal um estudo de caso interessante no contexto europeu. 
Palavras-chave: VIH; SIDA; Políticas da saúde; Serviços de saúde; Austeridade  
 v 
ABSTRACT  
Background: The current global health agenda for HIV/AIDS aims to mobilise countries 
worldwide to address major gaps in HIV response. UNAIDS has set ambitious targets to 
HIV treatment to be met by 2020. WHO recommends that evidence-based approaches 
and innovative strategies, including pre-exposure prophylaxis (PrEP) and HIV self-
testing (HIVST), should be part of countries’ response to the HIV epidemic. This 
unprecedented call for a global commitment against HIV/AIDS came in the aftermath of 
a severe global financial crisis that forced many countries to cut health care spending. 
This study aimed to analyse the potential effects of these financial constraints on the 
response to HIV/AIDS and associated national policies in Portugal, in the context of other 
Southern European countries that also received bailout programmes.  
Methods: For the purposes of this study, four analyses were conducted, using different 
methodological approaches: a) Hierarchical Poisson regression model with random 
effects was used to analyse the relation between length of stay and patient, treatment and 
setting characteristics, using national data from 20,361 hospitalizations occurring 
between 2009 and 2014 in 41 public hospitals in Portugal; b) For the period 2009-2018, 
we analysed the outcomes of HIV prevention programmes in Portugal which included: 
financial support to private non-for-profit organisations; syringe exchange programme; 
HIV rapid testing; and distribution of preventive materials; c) For the period 2005-2017, 
we analysed Portuguese HIV/AIDS surveillance data, using descriptive analysis and 
linear regression models to test for trends in new HIV and AIDS diagnoses and late HIV 
diagnoses; d) We examined and compared a set of HIV indicators in Cyprus, Greece, 
Portugal and Spain, countries which received economic assistance from the European 
Union during the financial crisis.  
Results: This study found that length of stay of HIV/AIDS patients in Portuguese public 
hospitals between 2010 and 2014 was significantly shorter compared to 2009, and that a 
number of variables, including being female, urgent admission, in-hospital mortality, 
pneumocystis pneumonia, hepatitis C, and hospital's current ratio contributed to the 
decrease of HIV/AIDS patients’ length of stay between 2009 and 2014. Findings also 
showed that, despite transitory spending cuts in 2012-13, the Portuguese HIV/AIDS 
Programme was able to improve its efficiency and sustain its core activities, thanks to 
prioritisation of spending in HIV testing expansion and a strong engagement with civil 
society organisations. The analysis of HIV trends between 2005 and 2017 has shown a 
significant decline in new HIV infections in all groups, except in men who have sex with 
men, where a non-significant increase trend was observed. Late diagnosis remains 
common in all transmission groups, except in MSM, while foreign acquisition of HIV is 
relevant among foreign-born persons, except in people who inject drugs. The comparative 
analysis with other three Southern European countries that received economic bailout 
assistance shows that Portugal is the only country that implemented both PrEP and 
HIVST. Portugal met the UNAIDS 90-90-90 targets for HIV treatment in 2017.       
Conclusion: Results from this study show that financial constraints experienced in 
Portugal have not hampered the country’s progress towards eliminating AIDS by 2030, 
making Portugal an interesting case study in the European context. 
Keywords: HIV; AIDS; Health policy; Health services; Austerity   
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1. GENERAL INTRODUCTION 
 
This dissertation is presented in three main chapters and consists of a set of four manuscripts 
that have been published or are currently under review. Each manuscript was written 
according to the format of the journal in which it was published or intended to be published.  
The first chapter (General Introduction) is divided into three subsections, which provide 
the background of the study, specify the study’s aims and objectives, and outline the 
methods.  
The second chapter (Results) is divided into four subsections, each one corresponding to a 
research paper.  
The third chapter (General Discussion and Conclusions) summarises the main findings and 
contributions of the dissertation, including its limitations, outlines the main policy 
implications, and draws the conclusions.  
 
1.1. Background 
1.1.1. Rationale of the study 
HIV remains a major global health concern. At the end of 2018, an estimated 37.9 [32.7-
44.9] million people worldwide were living with HIV and 1.7 million people were newly 
infected in 2018 globally [1]. In the WHO European Region, more than 2 million people 
were affected by HIV and nearly 160,000 were diagnosed with HIV in 2017, including 
25,000 in the European Union/European Economic Area (EU/EEA) [2].  
The goal of ending the AIDS epidemic by 2030 emerged in 2015 with the United Nations 
Agenda for Sustainable Development [3], but the momentum generated by the 
Millennium Development Goals was further developed with the WHO Global Health 
Sector Strategy on HIV for 2016-2021 [4] and with the Action Plan for the Health Sector 
Response to HIV in the WHO European Region [5]. Additionally, in 2015 the Joint 
United Nations Program on HIV/AIDS (UNAIDS) launched ambitious treatment targets 
to accelerate the end of the AIDS epidemic: by 2020, 90% of all people living with HIV 
will know their HIV status; 90% of all people with diagnosed HIV infection will receive 







sustained antiretroviral therapy, and 90% of all people receiving antiretroviral therapy 
will have viral suppression [6]. 
This new global health agenda for HIV was launched in the aftermath of the global 
economic crisis, the so called Great Recession, which began in the United States in mid-
2008. The crisis hit Europe severely in 2009 and generated a sovereign debt crisis that 
shook European Union Member States, particularly in the Eurozone [7]. The immediate 
response from several countries was the adoption of austerity measures, with cuts in 
public spending and tax raises. However, the vulnerability of some countries and the 
increasing difficulty in financing their economies led to several bailouts by the European 
Union (EU), European Central Bank (ECB) and the International Monetary Fund (IMF). 
This was the case for Greece, Ireland, Portugal, Spain and Cyprus [8]. These and other 
EU governments consequently have reduced spending dramatically, including for health 
expenditure. The economic crisis and the austerity period that followed have had political, 
financial, economic and social consequences that, ten years after, are still visible today.  
The global economic crisis and its possible consequences on HIV epidemics and national 
HIV policies, particularly in developing countries [9], have prompted deep concern from 
UNAIDS. Fears of limited access to treatment, strong risk of cuts in prevention 
programmes and possible reduction in donor assistance were highlighted as the main 
potential effects of the economic crisis in low-income countries [9].  
In Europe, the effects of the global economic crisis on the spread and control of 
communicable diseases was also subject of concern [10]. Many countries have cut 
budgets devoted to control and prevent infectious diseases, including HIV [11]. As 
investments in the HIV response were cut, in 2011 HIV outbreaks among people who 
inject drugs (PWID) were reported in Greece and Romania [12,13].  
HIV remains an important public health issue and Portugal is one of the EU/EEA 
countries with the highest number of newly diagnosed HIV cases [14]. The country’s 
commitment to steadily reduce HIV incidence and reach international standards on HIV 
treatment has not changed in the face of the economic crisis. However, the influence of 
the crisis and the austerity measures implemented in Portugal on the country’s response 
to the HIV epidemic have not yet been studied. People living with HIV (PLHIV) are a 
vulnerable group in constant need of appropriate and effective care, which is why the 






analysis of how the austerity measures imposed during the economic assistance 
programme to Portugal may have shaped the country’s HIV response and HIV policies 
constitutes a relevant case study.  
 
1.1.2. The global agenda for HIV/AIDS  
HIV/AIDS has become a global health priority [15]. What started at the very beginning 
as a small number of cases in homosexual men in California and New York, turned very 
quickly into a global epidemic, spreading  all over the world, but disproportionally 
affecting Sub-Saharan Africa [16]. The discovery of highly active antiretroviral therapy 
(HAART) in the mid-1990s helped to revert the increasing number of AIDS-related 
deaths in high-income countries, but mortality in low and middle-income countries 
continued to increase due to lack of access to ART [16]. By the beginning of the new 
millennium an estimated 34.3 million people were living with HIV/AIDS worldwide, 
24.5 million of which in Sub-Saharan Africa [17,18]. Since the beginning of the AIDS 
epidemic, an estimated 18.8 million people have lost their lives, including 3.8 million 
children [17].  
At the Millennium Summit, in September 2000, 189 member states of the United Nations 
adopted the Millennium Declaration, an unprecedented agenda to tackle extreme poverty 
in its many dimensions [19]. This agenda was translated into the Millennium 
Development Goals, which consisted of eight goals with measurable targets and clear 
deadlines that became the global development framework until 2015 [20]. HIV/AIDS 
was included in the Goal 6 (Combat HIV/AIDS, malaria and other diseases) and global 
efforts it made possible to decrease new HIV infections by 40% between 2000 and 2013 
(Target 6.A – Have halted by 2015 and begun to reverse the spread of HIV/AIDS) and to 
expand access to antiretroviral therapy (ART) to 13.6 million people living with HIV 
(PLHIV) in 2014, comparing to only 800,000 people in 2003 (Target 6.B – Achieve, by 
2010, universal access to treatment for HIV/AIDS for all those who need it) [20]. 
In June 2001, the United Nations (UN) General Assembly Special Session on HIV/AIDS 
endorsed a historic Declaration of Commitment on HIV/AIDS, where heads of State and 
representatives of governments agreed to prioritise the fight against HIV/AIDS and to 
provide prevention, treatment and care for all those suffering with the epidemics [21]. 
The meeting was a major milestone in the global response to HIV/AIDS and was renewed 







in 2011 [22]. As a result of this unprecedented commitment, the Global Fund to fight 
AIDS, Tuberculosis, and Malaria was created in 2002 to finance AIDS activities in 
developing countries [16]. One year later, in 2003, US President G.W. Bush announced 
the President’s Emergency Plan for AIDS Relief (PEPFAR), which allocated billions of 
dollars to countries most affected by AIDS [16].  
Created in 1994, the Joint United Nations Program on HIV/AIDS (UNAIDS) coordinated 
the efforts at the global level to tackle HIV/AIDS, but the 21st century brought several new 
actors to the field. The Millennium Development Goals catalysed the creation of numerous 
global health initiatives, many of them focused on HIV/AIDS [23]. These global health 
initiatives could be bilateral (eg PEPFAR) or multilateral agencies (eg The World Bank 
Multinational AIDS Programme) or even public-private partnerships (eg The Global Fund) 
and shared similar approaches in the application of funds targeting HIV/AIDS control in 
several countries and world regions [24]. When the 2008 economic crisis threatened the 
global HIV/AIDS response, and as donors were cutting funding to Global Health Initiatives, 
the role of non-governmental organisations, such as the Bill and Melinda Gates Foundation, 
was crucial to maintain adequate funding to HIV programmes.  
This unprecedented global response to the AIDS pandemic was successful in establishing 
multi-sectoral approaches involving several stakeholders and, thus, achieving a decline 
in HIV incidence and mortality [16]. Although there are arguments about the 
consequences of those “vertical” AIDS programmes on country health systems [23,25], 
collateral benefits include greater attention and funding for global health, especially for 
malaria and tuberculosis, and a strengthening of services for maternal and child health in 
some countries [26-28].  
Several actions were taken to accelerate the global response to HIV/AIDS, including the 
Global Plan towards the elimination of new HIV infections among children by 2015 and 
keeping their mothers alive, launched in 2011 with the aim to reduce new HIV infections 
among children by 90% from the baseline in 2009 [29]. The Global Plan included 21focus 
countries, that were home to nearly 90% of pregnant women living with HIV in need of 
services. By the end of 2015, 60% fewer children were newly infected with HIV annually 
compared to 2009 and over 2 million more pregnant women had started receiving 
lifesaving antiretroviral therapy [30]. 






Important progress was made in the fields of HIV treatment and prevention. Since the 
mid-1990s, the introduction of HAART has changed the treatment of PLHIV, with the 
life expectancy of an HIV-infected individual under treatment approaching the same as 
an uninfected individual [31-33]. The availability of several effective ART regimens and 
the availability of generic drugs, which are more affordable, made it possible to 
dramatically expand the number of people receiving ART [1]. As a result, AIDS-related 
deaths have started to decline, first in the USA and Europe and then in low and middle-
income countries [34]. Based on evidence of ongoing HIV replication on disease 
progression, the World Health Organization (WHO) recommended ART for all HIV-
infected individuals, irrespective of their CD4 count [35]. This was an important step 
towards the control of the HIV epidemic. On the one hand, PLHIV should be linked and 
retained in care right after diagnosis, without having to wait for a deterioration of their 
immunological status to initiate ART; on the other hand, it was shown that ART use 
prevents transmission of HIV in discordant couples [36], meaning that offering ART to 
all individuals infected by HIV could reduce the risk of their sexual partners. Hence, 
delivering ART to all PLHIV has a dual advantage: it protects the health and well-being 
of individuals infected by HIV and prevents them from transmitting the infection to 
others. As viral load is the greatest risk factor for all transmission modes (sexual, blood, 
mother-to-child) [37], treatment as prevention is based on the fact that ART can reduce 
plasma and genital HIV viral load to undetectable levels (viral suppression), thereby 
reducing infectiousness [36].  
HIV prevention strategies also witnessed major progress. Initially, the main prevention 
strategies were based on behavioural change (eg condom use, abstinence, reducing sexual 
partners) – with limited success [16], and harm reduction, which was highly effective in 
reducing HIV infections among PWID [38].  However, male circumcision was found to 
reduce susceptibility to HIV with an efficacy rate of 50 to 60% in three clinical trials [39-
41]. Male circumcision has proven to be one of the most cost-effective HIV prevention 
interventions with high rates of community effectiveness in decreasing HIV incidence in 
Sub-Saharan Africa [42,43]. But the greatest innovation in HIV prevention came from 
the use of antiretrovirals prior to sex as a way to reduce the risk of HIV acquisition by 
those who are HIV-negative. This is known as pre-exposure prophylaxis (PrEP) and there 
is growing evidence that the use of Tenofovir/Emtricitabine is effective in reducing the 







incidence of HIV in populations at high risk of HIV when taken as PrEP [44]. In 2015, 
WHO recommended PrEP as an additional prevention option for HIV negative people at 
substantial risk of HIV [45]. Additionally, WHO consolidated guidelines on HIV self-
testing and partner notification recommends the implementation of innovative approaches 
that include self-testing and testing provided by lay providers as part of overall HIV 
testing services [46]. 
The United Nations 2030 Agenda for Sustainable Development replaced the Millennium 
Development Goals, in 2015. The new 17 Sustainable Development Goals build on the 
achievements made previously. Target 3.3 sets an ambitious objective: “By 2030, end the 
epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases (…)” [3]. The 
Political Declaration on HIV and AIDS from 2016, sets the commitment to accelerate the 
fight against HIV and to ending the AIDS epidemic by 2030 [47]. In 2015, UNAIDS had 
set ambitious targets for HIV treatment to measure country progress towards that goal: 
by 2020, 90% of all people living with HIV will know their HIV status; 90% of all people 
with diagnosed HIV infection will receive sustained antiretroviral therapy, and 90% of 
all people receiving antiretroviral therapy will have viral suppression [6]. 
Launched in 2016, the WHO Global Health Sector Strategy on HIV for 2016-2021 
describes the health sector contribution towards the achievement of those targets and 
provides guidance to countries on how to accelerate and focus HIV prevention, enable 
people to know their HIV status, and provide ART and comprehensive long-term care to 
all PLHIV [4]. 
The world has witnessed remarkable progress towards the reduction of HIV/AIDS 
burden, particularly in the past two decades, thanks to an unprecedented global 
commitment that brought public health officials, community leaders, and politicians 
together to combat AIDS [16]. Scientific progress in HIV treatment and innovation in 
HIV prevention strategies made it possible to mobilise efforts towards ending the AIDS 
epidemic by 2030. The global health agenda for HIV is currently focused on preventing 
new HIV infections, increasing the number of PLHIV who know their status, providing 
ART to all PLHIV and having them virally suppressed. Ending the AIDS epidemic by 
2030 will require combined efforts, appropriate funding and the adoption of innovative 
strategies such as PrEP and HIV self-testing. More importantly, strong political will and 






sound policy monitoring are necessary to reach the most affected population groups in 
the local epidemic context and therefore to achieve a sustainable reduction in HIV 
incidence and an improvement in treatment outcomes.  
 
1.1.3. HIV/AIDS in Europe 
Europe is experiencing a persistent HIV epidemic, with little changes in notifications 
during the past decade in the EU/EEA. In 2017, the highest rates of new HIV diagnoses 
were reported in Latvia (18.8 cases per 100,000 population) and Estonia (16.6); while the 
lowest rates were reported in Slovakia (1.3) and Slovenia (1.9) [2] (Figure 1.1.1).  
 
 
Source: Author based on ECDC [2] 
Figure 1.1.1. Rate of new HIV diagnoses (per 100,000 population), EU/EEA, 2017.  
 
Sex between men is the main mode of HIV transmission reported in the EU/EEA in 2017, 
accounting for 38% of all new HIV diagnoses, while heterosexual contact was the second 
most common transmission mode among people newly diagnosed in 2017 (33%, equally 
divided between men and women); injecting drug use accounted for 4% of HIV diagnoses 







[2]. In 2017, 41% of those diagnosed in the EU/EEA were migrants, defined as those 
originating from outside of the country in which they were diagnosed, with 18% coming 
from countries in Sub-Saharan Africa, 8% from countries in Latin America and the 
Caribbean, 6% from other countries in central and eastern Europe, and 4% from other 
countries in western Europe [2]. 
Late diagnosis of HIV remains a problem in EU/EEA, with 49% of all cases with a CD4 
count available being diagnosed with a CD4 count below 350 cells/mm3; 28% of cases 
were considered to have advanced HIV infection (CD4 count < 200 cells/mm3) [2]. 
Although epidemic patterns and trends vary widely across EU/EEA countries, trends by 
transmission mode show that the number of new HIV diagnoses among men who have 
sex with men (MSM) decreased slightly in 2017 when compared to recent years [2]. The 
same happened with the number of heterosexually transmitted cases, with sharper 
declines among women and foreign-born heterosexual people than among men and non-
foreign-born people [2].  
In 2004, representatives of States and Governments from Europe and Central Asia 
adopted the Dublin Declaration, emphasising HIV as an important political priority for 
countries in Europe and Central Asia [48]. The declaration establishes the commitment 
of these countries to act collectively in tackling the HIV/AIDS epidemic and sets out a 
number of actions to accelerate the achievement of this commitment. The countries 
agreed to closely monitor and evaluate the implementation of the actions outlined in the 
Declaration, along with those of the UN Declaration of Commitment on HIV/AIDS [48]. 
The European Centre for Disease Prevention and Control (ECDC) conducted regular 
monitoring of the Dublin Declaration, every two years. However, following the UNAIDS 
mandate to report annually on this progress, it was agreed that ECDC would monitor the 
HIV response of EU/EEA countries annually from 2019 onwards.  
Building on the experience of the European Action plan for HIV/AIDS 2012–2015, the 
new Action Plan for the health sector response to HIV in the WHO European Region was 
launched in 2017 to guide Member States on the implementation of an essential package 
of HIV services that are people centred, accessible and appropriate to the national context, 
with a particular focus on key populations [5]. Based on global targets for HIV/AIDS, the 
Action Plan promotes a public health approach, with comprehensive HIV prevention and 






access to HIV testing, and also a “treat all” approach by offering treatment to all PLHIV, 
including children, adolescents, adults, pregnant and breastfeeding women, and people 
with coinfections [5]. 
In 2016, most EU/EEA countries had a policy to provide treatment regardless of CD4 
count, although this recommendation was implemented at a different pace across the 
countries [49]. However, the level of implementation of innovative interventions on 
testing (HIV self-testing) and prevention (PrEP) in EU/EEA is still weak. Given the HIV 
transmission patterns observed in those countries, the implementation of those 
interventions could have a crucial contribution to HIV response at the national level [2]. 
 
1.1.4. HIV response in Portugal 
Since the first case of HIV infection was reported in 1983, Portugal had recorded a total 
number of 57,913 HIV cases by 2017 [50]. In 2017, Portugal recorded the fourth highest 
HIV incidence rate (10.3 new HIV diagnoses per 100,000 population) among EU/EEA 
countries, after Latvia (18.8), Estonia (16.6) and Malta (10.4) [2].  
Portugal has a concentrated HIV epidemic. After reaching a peak in 1999, when the 
epidemic was mainly driven by cases among people who inject drugs (PWID), the number 
of both new HIV and AIDS diagnoses in Portugal has been decreasing steadily (Figure 
1.1.2). Heterosexual contacts are the most frequent mode of HIV transmission identified 
among all cases diagnosed in recent years; however, sex between men recently exceeded 
heterosexual transmission amongst male cases [50].  As in other EU/EEA countries, late 
diagnosis is common as well as new HIV diagnoses among older age groups (50 years or 
older) [50].   
The country’s national response to HIV started in 1985, when the first AIDS Working 
Group was established [51]; and in that same year, a national surveillance system of HIV 
infection was enacted, making it possible to compare the Portuguese HIV epidemic with 
other European countries. HIV/AIDS is a mandatory notifiable disease in Portugal since 
2005 [52], and the national database of all HIV and AIDS cases reported in Portugal is 
maintained by the National Institute of Health (Instituto Nacional de Saúde Doutor 
Ricardo Jorge, INSA), which is the national reference laboratory of the Ministry of 
Health. 







ART has been fully covered by the universal National Health Service (NHS) and foreign 
citizens living in Portugal have legally the same access to NHS services, including ART, 
following the same conditions as national citizens. HIV drugs are generally provided at a 
hospital setting, although the provision at community pharmacies is currently being 
studied. 
 
Source: INSA [50] 
Figure 1.1.2. Number of new HIV and AIDS diagnoses, Portugal, 1983-2017.  
 
The National Commission for the Fight Against AIDS (Comissão Nacional de Luta 
Contra a SIDA) was created in 1990 to replace the first AIDS Working Group. It became 
the official body responsible for coordinating Portugal’s HIV response, focusing on 
prevention, education, research and surveillance [53].   
Since the establishment of the National Commission for the Fight Against AIDS, the 
country has implemented several policies on HIV, approved new legislation, and 
developed and implemented new programmes. Enacted in 1993, the Syringe Exchange 
Programme has been the most important harm reduction policy implemented in Portugal 






























































































Voluntary Testing and Counselling Centres (Centros de Aconselhamento e Deteção, 
CAD) was launched, with the purpose of delivering services for voluntary, anonymous, 
confidential and free HIV testing, as well as pre- and post-counselling.  
In 2005, the National Commission Against AIDS was replaced by the National 
Coordination for HIV/AIDS Infection, within the newly created High-Commissariat for 
Health [55,56]. This body was intended to provide technical support to policymaking and 
strategic planning, and its terms of reference also included the coordination of the four 
vertical programmes: Cardiovascular diseases, Oncologic diseases, Mental health, and 
HIV/AIDS [57]. The National Coordination for HIV/AIDS Infection was responsible for 
HIV/AIDS surveillance, leading an integrated information system created for that 
purpose, as well as acquiring and distributing prevention materials, including syringes, 
condoms and rapid tests.  
Following the abolition of the High Commissariat for Health in 2011, the National 
Programme for HIV/AIDS Infection was created as part of a set of priority health 
programmes run by the Directorate-General of Health (Direção-Geral da Saúde, DGS) 
[58]. The National Programme for HIV/AIDS Infection coordinates national HIV 
response, maintaining the same attributions as its predecessor,  and its strategic guidelines 
are aligned with the UNAIDS goals [59,60].  
 
1.1.5. The Great Recession 
Very few non-health events have had such a tremendous impact on the health of the 
populations as the so-called Great Recession; firstly, due to the global nature of the 
economic and financial crisis affecting many countries; and secondly, because of its 
consequences on social determinants of health.  
The global crisis had multiple causes, and although this is not the scope of this work, it is 
important to provide a quick overview on what triggered such an overwhelming event. 
Authors agree that the expansionary monetary policy was the trigger for the asset price 
bubble of the housing price boom [61]. In fact, by lowering interest rates and inducing 
borrowing to acquire asset, monetary policy in the USA (but also in Europe) created the 
conditions to the eventual disruption of credit flows. While Americans were buying 
houses helped by mortgage lending, these loans were given to subprime borrowers. This 
was another cause of the financial crisis: the use of new financial instruments [62]. 







Besides subprime loans, these innovative investment instruments included securitisation, 
derivatives and auction-rate securities, which were adopted before markets became aware 
of the flaws in these instruments, particularly the basic one: determining their price [61]. 
Both derivatives and mortgage-backed securities were difficult to price: a pool of 
mortgages was assumed to give the securities value, but as that pool was an assortment 
of mortgages of varying quality, it was hard to price the pool. Rating agencies also had 
no formula to determine the price of the security, and assigned ratings to complex 
securities, without examining the individual mortgages in the pool [61,62]. Those ratings 
tended to overstate the value of the securities and were pretty much arbitrary [61]. From 
the mortgage industry, the securitisation of mortgage loans quickly spread to commercial 
paper issuance, student loans, credit card receivables, and other loan categories, making 
the problems worse.   
The origins of the global financial crisis can be traced back to 15 September 2008, when 
the collapse of Lehman Brothers, the fourth-largest investment bank in the United States 
(US), unfolded an unprecedented financial crisis that spread mainly through the USA and 
Europe [63]. In Europe, however, a number of countries had been sharing the same 
currency since 2002, limiting their capacity to withstand negative macroeconomic and 
financial shocks [7]. The European monetary union was never accompanied by a significant 
degree of banking or fiscal union, and this has been pointed as the major challenge of the 
Euro since the very beginning [64]. Euro countries have limits to their annual budget deficit 
(3% of GDP) and to their stock of public debt (60% of GDP), according to the Stability and 
Growth Pact designed in the beginning of this century, which also limits the ability of 
countries to deal with macroeconomic and financial shocks [7]. The design flaws of the 
Euro were to be exposed when the Great Recession came. As argued by some authors, 
Europe faced three different crises combined: a banking crisis in the Euro area, a growth 
crisis and a sovereign debt crisis [65]. Those three crises were closely interlinked. Firstly, 
because the banking system was insolvent, governments were called to support the banks 
in an attempt to contain the damages of a collapsing banking system. That worsened the 
countries’ sovereign debts. Also, attempts at fiscal austerity to relieve the problems due to 
sovereign stress slowed economic growth (already hampered by a banking system in crisis) 
and economies faced stagnation or recession. In summary, macroeconomic imbalances in 






many Euro countries, coupled with a severe banking crisis, created a serious sovereign debt 
crisis that engulfed the Eurozone in 2010 [7]. 
As countries were struggling to repay or refinance their government debts, several 
austerity packages were implemented by governments pressured at EU level to control 
spending and raise revenue. The term austerity was widely used by media, politicians, 
academia and citizens to characterise the actions taken by governments during the Great 
Recession. The aim of economic austerity is to reduce a country’s structural deficit [66]. 
Therefore, austerity measures include a combination of public expenditure reductions and 
increased taxes. The fundamental problem with this approach was the implementation of 
economic austerity at the bottom of the business cycle. After the turmoil generated by the 
2008 financial crisis, global financial markets were demanding austerity in order to 
prevent defaults from governments [66]. However, one of the major consequences of 
economic austerity was the fact that it slowed growth and recovery.  
The creation of the European Financial Stability Facility and the European Financial 
Stabilisation Mechanism in May 2010 (later replaced by the European Stability 
Mechanism in 2012) enabled financial assistance programmes for member states of the 
Eurozone struggling with financial difficulties. 
Several countries in Southern Europe were particularly affected by the crisis. In May 
2010, Greece received a bailout by the European Commission, European Central bank 
and International Monetary Fund (IMF): the Greek government and the three institutions 
agreed on a EUR 110 billion loan over a three-year period. Overall, Greece received a 
bailout of EUR 310 billion over three assistance programmes between May 2010 and 
August 2018 [67]. From 2011 until the end of 2013 the European Union and the IMF 
provided financial assistance to Ireland, including a joint financing package of EUR 85 
billion (EUR 67.5 billion from external sources and EUR 17.5 billion from Irish funds) 
[68]. A few months later, in May 2011, Portugal requested financial assistance and a EUR 
78 billion loan was part of an assistance programme that ended in May 2014 [69]. In July 
2012, Spain also requested a bailout in order to recapitalise its financial institutions. The 
assistance programme lasted for 18 months and involved a bailout of EUR 41.3 billion 
[70]. Finally, after months of negotiation on the bailout terms, Cyprus received a EUR 10 
billion loan in March 2013 [71]. The Cypriot programme lasted until March 2016. Other 
EU countries out of the Eurozone received bailouts as a result of the global economic 







crisis, including Hungary (October 2008, EUR 20 billion), Latvia (January 2009, EUR 
2.9 billion), and Romania (June 2009, EUR 20 billion) [72]. 
The legacy of the crisis and economic austerity was overwhelming. Evidence suggests 
that the financial crisis has permanently lowered the path of GDP in all advanced 
economies and, simultaneously, fiscal consolidations implemented in many countries 
have had a negative impact on their growth rates [73]. Austerity also had severe 
consequences on jobs and income loss in the initial period. The turn to austerity hurt many 
countries’ economies and hampered growth when the crisis was over [74]. 
 
1.1.6. Consequences on health status and health care systems 
The consequences of the economic and financial crisis on the health of citizens and health 
care has been studied across Europe [75-77] and the subject has generated intense debate. 
However, findings of these research are very controversial. Following the onset of the crisis, 
a rise in suicides has been observed in Greece, Spain, the UK, and the USA [78-81]; and a 
rise in mental health disorders has been observed in Greece and Spain [82-84]. Literature also 
suggests that cases of infectious disease, homicides, substance abuse, and poor self-reported 
health have increased in Greece [78,85-87]. In contrast, evidence from studies that assessed 
the effects of economic cycles, showed that economic crisis reduce mortality related to road 
traffic accidents and cardiovascular events [88]. A recent literature review has concluded that 
the financial crisis in Europe seemed to have had heterogeneous effects on health outcomes, 
with the evidence being most consistent for suicides and mental health [89]. However, 
authors highlighted that most published studies on the impact of financial crisis on health in 
Europe had a substantial risk of bias [89].  
The impact of the financial crisis on health care systems has also been the subject of 
research in recent years. The effects of the crisis on health care utilization are unclear, 
due to lack of measures to monitor the impact of the crisis and its consequences on health 
status and health care. From the demand side, income reductions could have had an 
impact in the use of health care services, as international evidence shows that low-income 
people have a higher use of in-patient care [90], and longer in-patient stays [91], due to 
deterioration of their health status. From the supply side, budget cuts could have led 






hospitals to reduce inefficiencies but also to decrease quality of health care provided, for 
instance by shortening the length of stay or reducing the number of admissions.  
The available evidence for Portugal suggests a deterioration in access to health care since 
austerity measures were implemented in 2011, especially for vulnerable population 
groups not benefiting from exemptions in user charges [92]. The same applies to other 
countries in Southern Europe, particularly Greece and Spain [93,94], where austerity 
measures affected universal health coverage, population health and the welfare state [95]. 
The Portuguese health system is characterised by three co-existing systems: the universal 
National Health Service (NHS); the health subsystems, health insurance schemes for 
which membership is based on professional/occupational group or company; and private 
voluntary health insurance (VHI) [96]. It draws on a mix of public and private financing: 
the NHS is predominantly financed through general taxation; the health subsystems are 
financed mainly through employee and employer contributions and private VHI has a 
supplementary role. Given the importance of the public sector in the health system, the 
Memorandum of Understanding (MoU) signed in 2011 between the Portuguese 
government and the three international borrower institutions included a series of measures 
specifically targeting the health sector [97]. Overall, measures in the MoU aimed to cut 
costs and increase efficiency.  
The specific measures included financing of the NHS and public sub-systems. From 2005 
to 2010, the NHS budget increased steadily, both in absolute value and in proportion of 
GDP (Figure 1.1.3). However, during the financial assistance programme, the NHS 
budget decreased significantly: -12% between 2010 and 2014 (Figure 1.1.3). By 2011, 
public hospital’s debt to suppliers reached EUR 3 billion [98]. This situation called for a 
special programme of debt settlement in 2012 and 2013, in a total amount of EUR 1.9 
billion (Figure 1.1.3). 
The increase of user charges in the NHS was probably the most debated measure. In 2010, 
user charges represented 0.74% of the NHS total revenue but in 2012 that figure raised 
to 1.70% [96]. However, exemption rules for user charges payment were also reviewed 
to include not only patients with chronic conditions (e.g. cancer, HIV, etc.) but also 
patients with low-income [99]. Although around 60% of the Portuguese population was 
exempted of paying user charges to use the NHS, those not included in an exemption 
category were paying much more to use publicly provided health care [96,99]. 









Source: Ministry of Health 
Figure 1.1.3. Budget execution in the Portuguese National Health Service (Million EUR), 
2006-2017.             
 
The pharmaceutical market reform, also inscribed in the MoU, had the objective of 
lowering government expenditure through a set of instruments: tougher pricing rules, 
promotion of generic drugs, reduction in the distribution margins and more rational 
prescription patterns by doctors [100]. However, the crucial measure that helped to 
contain costs in the Portuguese National Health Service was in fact applied to all public 
sector in Portugal: hiring of new personnel was limited, wages were frozen and additional 
wage cuts through taxation were imposed [96]. Additionally, in the health sector, the 
number of weekly working hours was increased from 35 to 40, without any effect in 
salaries. Between 2010 and 2015, the salary variation in the NHS was -9% and the 
variation of the number of professionals was -1% [101]. 
Other countries financially assisted by the EU felt the impact of the crisis and austerity 
measures on their health systems. In Greece, most of the measures introduced during the 
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first wave of reforms (2010-14) were fiscal consolidation measures, resulting in 
increasing barriers in accessing health care and a deterioration of the population health 
[102]. In fact, between 2009 and 2016, 2.5 million Greeks (those who became 
unemployed for more than two years and their dependents, as well as the self-employed 
who could no longer afford to pay contributions) are estimated to have lost their health 
insurance coverage and, therefore, experienced barriers to access publicly provided 
services [102]. Like in Portugal, austerity measures imposed cuts in public expenditure 
with negative impacts on quality of health care provision, and human resources for health 
have been affected by salary cuts, hiring freezes and brain drain [102]. The health of the 
Greek population deteriorated as socioeconomic conditions got worse, with 
unemployment rate reaching 27.5% in 2013 [102]. The mental health of the population 
has deteriorated and suicide rates have increased during the crisis [103]. Furthermore, 
there was a substantial increase in HIV infections between 2009 (5.5 per 100,000 
population) and 2012 (10.3 per 100,000 population) [104]. The increase in HIV incidence 
in Greece was mainly due to an HIV outbreak among injecting drug users, with the 
number of new HIV infections in this population increasing 15-fold from 2010 to 2011. 
This outbreak was linked to cuts in prevention programmes and deteriorating 
socioeconomic conditions [104-106].  
In Cyprus, the financial crisis has also resulted in severe cuts in overall health expenditure 
[107]. The 2013 Economic Adjustment Programme for Cyprus formulated a number of 
recommendations regarding the health care sector aimed at increasing quality and 
efficiency of public health care provision in the country. These included changes to user 
charge policy and public sector eligibility with the objective of both raising revenues and 
reducing unnecessary demand for services [107]. Regarding HIV infection, there is 
evidence of increasing HIV incidence after 2014 [2]. Reports from 2014 mention the 
annual budget for medications, which is part of the government’s budget as the country 
does not have a national health system, was cut from EUR 190 million to EUR 90 million 
[108].  
In 2012, Spain requested financial assistance to the EU for the recapitalisation of financial 
institutions. Although targeting the banking system, the bailout was coupled with a series 
of austerity measures. Between 2009 and 2015, government expenditure on health 
decreased by 5.3% [109]. New legislation approved in 2012, re-defined who is entitled 







to health care, linking the entitlement to contributions to the system, and, thus, excluding 
young people over 26 who have never entered the job market and illegal immigrants from 
receiving health care [110]. Notwithstanding, the Spanish health system remains almost 
universal, covering 99.1% of the population [109]. During the crisis, HIV incidence in 
Spain declined from 11.2 new cases per 100 000 inhabitants in 2009 to 7.4 new cases per 
100 000 inhabitants in 2015 [109]. 
Overall, the impact of the financial crisis and austerity measures on health systems in the 
countries that received financial assistance from the EU was different, according to the 
specific characteristics, strengths and fragilities in each health system. The same may 
apply to the impact on HIV policies in each country. 
 
1.2.  Study Aim and Objectives 
The main aim of this study was to analyse the role played by the economic and financial 
assistance programme implemented in Portugal between 2011 and 2014 on the country’s 
HIV response and national HIV policies.  
To study the influence that financial constraints and cuts in health expenditure operated 
in this difficult period may have had on HIV epidemic, provision of preventive and 
treatment services and adoption of international recommendations is important not only 
to characterise Portugal’s progress in eliminating AIDS by 2030, but also to draw policy 
implications to guide decision makers in the event of future economic downturns.  The 
comparison with other countries that experienced EU assistance programmes is also 
important to place findings in an international perspective.  
Specific objectives of this dissertation were:  
1. To analyse the potential impact of the economic and financial adjustment 
programme on the length of stay of HIV/AIDS patients in public hospitals; 
2. To analyse the outcomes of core HIV prevention programmes managed by the 
National Programme for HIV/AIDS Infection; 
3. To analyse national HIV surveillance data, in order to better understand 
transmission patterns and identify red flags; 
4. To examine and compare a set of HIV indicators and implementation of core HIV 
policies in Cyprus, Greece, Portugal and Spain.  






1.3.  Methods 
This study used a quantitative methodology, using secondary national databases provided 
by different Ministry of Health institutions. The detailed methods used in each study are 
detailed ahead (see Section 2. Results).  
The national data – either routine health information systems or national surveillance data 
– provide accurate opportunities for secondary data analysis [111]. These data have the 
potential to provide accurate, reliable, representative and continuous information on the 
health system and its patients [112-114]. Data collected as part of a public health 
surveillance system can be used to estimate the magnitude of a problem, identify groups 
at higher risk of having poorer outcomes, and examine relationships between risk factors 
and outcomes [115]. Furthermore, national surveillance data allow for tracking responses 
to policy changes in HIV testing, ART uptake, and progress in achieving the UNAIDS 
90-90-90 targets for ending AIDS [116]. Summing up, the usage of national data is useful 
to inform programmes and policy making on HIV/AIDS.  
For the purpose of this study, a set of dimensions of HIV policies were included in the 
analysis: 
• General health care – Hospitalisations of HIV patients intended to capture the 
universal provision of healthcare within the Portuguese National Health Service; 
• HIV prevention and diagnosis – Activities of the HIV/AIDS Programme include 
a set of prevention programmes including the syringe exchange programme, HIV 
rapid testing, preventive materials (male and female condoms, and lubricant), and 
also financial support to civil society organisations providing preventive services; 
• HIV surveillance – Analysis of national surveillance provides information on 
major trends in Portugal, and allows the identification of key populations for 
whom prevention efforts can be strengthened; 
• HIV prevention, HIV diagnosis, HIV treatment and care – Analysis of core 
indicators such as the adoption of Treat All recommendation, 90-90-90 targets, 
and implementation of pre-exposure prophylaxis and HIV self-testing is important 
to measure progress on ending AIDS by 2030. 
Table 1.1.1. outlines the methods and data sources for each study.  
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2.1.  Impact of the economic and financial adjustment programme in 




The economic and financial crisis that started in 2008 reached Portugal in 2009 and had 
economic and social consequences that are still felt to this day. Portugal has experienced 
recessions in 2009 (-2.98% in GDP), 2011 (-1.83%), 2012 (-4.03%) and 2013 (-1.13%) 
and this was accompanied by a dramatic rise in the unemployment rate, which rose from 
7.6% in 2008 to 16.2% in 2013 [1]. Due to the high level of public debt and the increasing 
difficulty in financing its economy, the country received a financial bailout by the 
European Commission, the International Monetary Fund and the European Central Bank 
[2]. 
In the Memorandum of Understanding (MoU) signed with the three institutions above, 
the Portuguese government compromised by implementing a number of reforms aimed 
at reducing public spending. With regard to the health sector, the MoU set a number of 
measures aimed at cost containment and increasing efficiency within the Portuguese 
National Health Service (NHS) [3]. These included severe cuts in the wages of health 
care worker; the creation and implementation of clinical guidelines; the reorganisation 
and rationalisation of the hospital network through specialisation and concentration of 
hospital and emergency services; and setting up a system for comparing hospital 
performance (benchmarking) [4]. 
The consequences of the economic and financial crisis on the health of the citizens and 
health care has been studied all over Europe [5-7] and has generated intense debate. 
However, the impact of these events on health care use is still unclear, mainly due to lack 
of measures to monitor the impact of the crisis and its consequences on health and health 
care. From the demand side, one could argue that income reductions could have an impact 
in the use of health care services, as international evidence shows that low-income people 
have a higher use of in-patient care [8], and longer in-patient stays [9], due to deterioration 








inefficiencies but also to decrease quality of health care provided (e.g. by reducing length 
of stay or decreasing the number of admissions). 
The impact of the crisis on the health of the population has been the focus of recent 
research but findings are very controversial. Following the onset of the crisis, a rise in 
suicides has been observed in Greece, Spain, the UK, and the USA [10-13]; and a rise in 
mental health disorders has been observed in Greece and Spain [14-16]. Literature also 
suggests that there has been an increase in cases of infectious disease, homicides, 
substance abuse, and poor self-reported health in Greece [10,17-19]. In contrast, there is 
evidence showing that economic crisis is associated with reduced mortality related to road 
traffic accidents and cardiovascular events [20]. 
The existing evidence suggests that since austerity measures came into effect in 2011 
there has been a decline in access to health care in Portugal, particularly among vulnerable 
population groups who do not benefit from user charges exemptions [21]. Other Southern 
European countries, namely Greece and Spain [22,23], experienced a similar situation 
and witnessed a serious setback in terms of the universal health coverage, population 
well-being and welfare state as a result of austerity measures [24]. 
The crisis led many countries to reduce budgets earmarked for control and prevention of 
infectious diseases, including HIV [25,26]. People living with HIV (PLHIV) are 
vulnerable group who need constant hospital care both outpatient and inpatient) and, 
therefore, constitute a relevant case study to evaluate how the austerity measures imposed 
by the MoU had an impact in health care provision. As PLHIV are living longer and 
experiencing age-associated comorbidities, hospitalizations have become an important 
indicator of healthcare expenditure in these patients. As in the rest of the world, in 
Portugal HIV-related hospitalizations are among the most expensive. In 2008, the average 
cost of treatment was 14,277 EUR/patient/year, with the main cost-driver being ART 
(EUR 9,598), followed by hospitalization costs (EUR 1,323) [27]. In addition, the weight 
of hospitalization costs was considerably higher for the most severely affected patients 
[27]. 
By identifying and characterising the variations in length of stay (LOS) among 
HIV/AIDS hospitalizations across different Portuguese hospitals, the aim of this paper 
was to analyse the potential impact of the economic and financial adjustment programme 
(EFAP) on HIV/AIDS patients LOS. 







2.1.2.1.  Data source 
Data used in this analysis were collected from the Portuguese national database of the 
diagnosis related groups (AP-DRG v21.0) managed by the Central Administration of the 
Health System (ACSS). The DRG database is anonymous and available for scientific 
research. DRGs were first introduced in Portuguese hospitals through a pilot study in 
1984 and, since the 1990s, DRGs are used for DRG-based hospital budget allocation from 
the NHS to hospitals and for DRG-based case payment from third-party payers [28]. 
Currently, there is only one DRG system in Portugal that applies to all NHS hospitals 
(public) and all patients (inpatients and ambulatory surgery), with exception of 
outpatients and patients treated in psychiatric and rehabilitation healthcare settings. 
Private hospitals are not included in the system. The DRG system currently in place 
defines 669 DRGs within 25 Major Diagnostic Categories (MDCs), each corresponding 
to one organ or physiological system [28]. The DRG system is supervised and maintained 
by the ACSS within the Ministry of Health. 
In the DRG database, each record corresponds to a discharge episode (hospitalization) 
and includes information about the patient as well as information collected during the 
hospitalization, including age, sex, place of residence, type of admission (elective or 
urgent), dates of hospitalization and discharge, principal diagnosis and secondary 
diagnosis, procedures during hospitalization, and outcome at discharge (dead or alive). 
 
 
2.1.2.2.  Study population 
We considered only discharges classified under MDC created for patients with HIV 
infection (MDC 24). Thus, the dataset provided by the ACSS included 20,580 discharges 
registered in public acute care hospitals in the Portuguese NHS classified under MDC 24, 
between 1st January 2009 and 31st December 2014. For this study we considered only 
those that met the following criteria: inpatients aged 18 or older; hospitalizations from 
hospitals with more than 10 discharges. Following these criteria, 20,361 hospitalizations 
occurring in 41 hospitals were included in the analysis (Figure 2.1.1). 
Unlike previous studies [29,30], transfers were not excluded from the analysis in order to 








hospitalizations in smaller hospitals followed by longer hospitalizations in bigger 
hospitals were all included in this analysis. Length of stay was considered for each patient 
discharged, including patients transferred between different hospital centres (LOS was 
not summed), in order to capture all hospitalizations. Transfers between hospitals 




Figure 2.1.1. Selection profile of study population. 
 
 
2.1.2.3.  Outcomes and covariates 
The outcome variable was the number of days between hospital admission and discharge 
dates (LOS). The main explanatory variable was the year, as we aimed to examine the 
impact of the EFAP, which was implemented in Portugal between May 2011 and May 
2014. 
We examined three types of covariates: patient, treatment and setting variables. 






Ø Patient covariates considered were: gender, age (at the date of admission), region 
of residence, type of admission (elective or urgent), readmission within 30 days 
of discharge, in-hospital mortality, presence of selected co-infections 
(Pneumocystis pneumonia, Hepatitis B, Hepatitis C, and Tuberculosis), 
HIV/AIDS as principal diagnosis at admission, and the number of secondary 
diagnosis (obtained as a sum of diagnosis apart from the main diagnosis, in 19 
possible cases [29,31]); 
Ø Treatment covariates included: number of procedures (obtained as a sum of 
procedures in 20 possible cases [29,31]); 
Ø Setting covariates included whether the hospital was merged into a Hospital 
Centre or not, and the hospital’s current ratio 
Pneumocystis pneumonia became a common manifestation of HIV infection in the 
developed world during the 1980s, and frequently resulted in death. Following the 
introduction of highly active antiretroviral therapy (HAART) in 1996, there was a 
dramatic decline in the incidence of opportunistic infections in HIV/AIDS patients 
(including Pneumocystis pneumonia). However, despite the major benefits associated 
with HAART, Pneumocystis pneumonia remains one of the most common AIDS-
defining diagnoses and most common causes of AIDS-related death, especially in HIV-
infected patients who present late into medical care [32]. Hepatitis B and Hepatitis C are 
also common co-infections among people living with HIV. The estimated prevalence of 
hepatitis B among people living with HIV is 5–20%; thus, approximately 2 to 4 million 
people living with HIV worldwide have chronic hepatitis B coinfection [33,34]. It is 
estimated that hepatitis C affects 2–15% of people living with HIV worldwide (and up to 
90% of those are people who inject drugs [35]. Likewise, Tuberculosis and HIV/AIDS 
constitute the main burden of infectious disease in resource-limited countries [36]. Some 
14 million individuals worldwide are estimated to be dually infected with HIV and 
Tuberculosis [37] and TB remains the leading cause of death among people living with 
HIV [38]. The DGR database records the principal and all secondary diagnosis (up to 19) 
from each discharge using ICD-9 codes. Table 2.1.1  shows the ICD-9 codes used to 










Table 2.1.1. ICD-9 codes and description for the selected diagnosis. 
ICD-9 codes Description 
070.2 – 070.3 Hepatitis B 
070.7 Hepatitis C 
042 Human immunodeficiency virus (HIV) infection  
136.3 Pneumocystosis 
010 – 018 Tuberculosis 
 
In the beginning of the 2000s, the NHS hospital network was reformed. Firstly, hospitals 
were transformed in public enterprises (2005) with the aim of promoting autonomous 
management and improve efficiency. Secondly, some hospitals were grouped into 
Hospital Centres. The rationale behind the creation of Hospital Centres was to improve 
efficiency through better coordination between institutions providing hospital care in the 
same geographical area [39]. The process of merging hospitals took place over for several 
years, this explains why there were important changes during the study period (2009–
2014): in 2009 there were 46 hospital institutions and in 2014 there were 41, and therefore 
different codes in the dataset provided by ACSS correspond currently to the same 
Hospital Centre. In order to have the same number of institutions during the study period, 
hospitals were coded according to their current status, as to simulate the Hospital Centre 
of which they are currently part of, and a dummy variable was added to measure the effect 
of this merger. 
Finally, a variable measuring the hospital’s financial situation was added to this analysis. 
The current ratio is a liquidity ratio that measures a company’s ability to pay short-term 
and long-term obligations. To measure this ability, the current ratio considers the current 
total assets of a company (both liquid and illiquid) relative to that company’s current total 




The annual current ratio for each hospital institution in the DRG dataset was taken from 
the annual report and accounts from each hospital between 2009 and 2014. 






2.1.2.4. Statistical analysis  
The skewness and heterogeneity of LOS is a challenge for statistical analysis [41,42]. 
Particularly, HIV/AIDS LOS has 6–7% of outliers and its distribution is very asymmetric 
[31]. LOS has been analysed using many different methods. For example, Barbour et al. 
studied changes among HIV/AIDS inpatients using a multivariable linear regression 
model [43], while Huang et al. analysed LOS and costs based on a generalised linear 
mixed model [44]. Other authors, like Wang et al., analysed maternity LOS from a two-
component Poisson mixed model [45]. However, researchers must take into consideration 
that hospitalizations from the same hospital are often correlated, since ignoring the 
dependence of clustered data may lead to illegitimate associations and false 
interpretations [45]. 
Hierarchical Poisson regression model was specified to analyse the relation between LOS 
and the covariates. In DRG data, patients are nested within hospitals on the basis of their 
own choices which can range from place of residence, trust in a particular doctor, or even 
the hospital’s reputation. This important element breaks the independence assumptions 
of classical regression analysis. Hence, hierarchical modelling is considered a more 
suitable statistical method when using multilevel structured data, like patients clustered 
within hospitals [46]. Additionally, the recognition of hospital random effects, which are 
nevertheless important, can be used to explain variations in hospital quality/performance 
[42]. 
Let  	y34	(i = 1, 2, …m; 	j = 1,2,…	n3)	the count variable (LOS) of the jth observation 







is the sample size. The generalised linear model takes the form:    
 θ34 = η34 = χ34β + ν3 
 
where χ34 is vector with covariates with regression coefficients	β, and νJ is assumed to be 








We used a mediation analysis to check if year dummies vary whether the current ratio is 
included or not. 
All statistical analyses were performed using statistical software R and its library MASS 




The overall median length of stay (LOS) was 11 days (IQR = 16). Table 2.1.2 shows the 
summary statistics of hospitalization according to discharge episodes characteristics. 
Out of 20,361 discharges, 14,628 (71.8%) were male and the median age was 44 years 
(IQR = 15). During the study period, the median number of secondary diagnoses was 7 
(IQR = 5) and the median number of procedures was 8 (IQR = 7). The majority of 
hospitalizations corresponded to patients living in the Lisbon and the Tagus Valley region 
(53.3%). During the study period (2009–2014), there was a steady decrease in the number 
of hospitalizations (Table 2.1.2), while the majority corresponded to urgent admissions 
(83.4%). The most common HIV-related infections among hospitalizations between 2009 
and 2014 were tuberculosis (43.6%) and hepatitis C (28.0%). In-hospital mortality during 
the same period was 12.6%. 
The hierarchical Poisson model as estimated by penalised quasi-likelihood and the 
majority of covariates have a significant impact in LOS (Table 2.1.3). Although age is 
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In contrast with the estimated coefficient of the variable that measured hospital mergers, 
estimated coefficients of year dummies remained statistically significant after introducing 
the variable current status in the model (Table 2.1.3). Thus, adjusting for other factors, 
patients hospitalized during 2010 and 2011 had an estimated LOS 0.092 and 0.109% 
lower, respectively, than those hospitalized in 2009, while patients hospitalized in 2012, 
2013 and 2014 had an estimated LOS 0.186, 0.268 and 0.262% lower than those 
hospitalized in 2009 (Table 2.1.3). 
Adjusting for other variables, estimated LOS was lower for hospitalizations resulting in 
death, for women, and for patients with urgent admission (Table 2.1.3). Patients with 
urgent admission had an estimated LOS 0.068% lower than those with elective admission 
(Table 2.1.3). In contrast, patients with higher number of diagnosis (or higher number of 
procedures) have a higher estimated HIV/AIDS LOS. Adjusting for other variables, one 
additional number of secondary diagnosis increased LOS by 0.043%, while one 
additional number of procedures increased LOS by 0.085% (Table 2.1.3). 
Adjusting for other factors, when analysing selected co-morbidities, patients co-infected 
with Pneumocystis pneumonia and hepatitis C had an estimated LOS 0.129 and 0.126% 
shorter, respectively, than those without those co-infections (Table 2.1.3). In contrast, 
patients co-infected with tuberculosis had an estimated LOS 0.391% longer than those 
without TB. Finally, patients having HIV/AIDS as a principal diagnosis had an estimated 






















               Model 1                Model 2 
Coefficient p-value Coefficient p-value 
Intercept 1.668 <0.001 1.837 <0.001 
Gender (Female)  -0.041 0.001  -0.039 0.011 
Age -0.001 0.118 -0.001 0.137 
Year 2010 (reference 2009) -0.060 0.006 -0.092 <0.001 
Year 2011 (reference 2009) -0.068 0.003 -0.109 <0.001 
Year 2012 (reference 2009) -0.135 <0.001 -0.186 <0.001 
Year 2013 (reference 2009) -0.214 <0.001 -0.268 <0.001 
Year 2014 (reference 2009) -0.238 <0.001 -0.262 <0.001 
No. secondary diagnoses 0.044 <0.001 0.043 <0.001 
No. procedures 0.084 <0.001 0.085 <0.001 
Urgent admission -0.069 <0.001 -0.068 <0.001 
Readmission within 30 days -0.039 0.079 -0.040 0.080 
In-hospital mortality -0.139 <0.001 -0.142 <0.001 
HIV/AIDS as principal 
diagnosis 
0.084 <0.001 0.085 <0.001 
Pneumocystis pneumonia -0.131 <0.001 -0.129 <0.001 
Hepatitis C -0.126 <0.001 -0.126 <0.001 
Tuberculosis 0.392 <0.001 0.391 <0.001 
Hospital merge 0.081 0.001 0.046 0.066 








Hospital random effects were estimated to capture differences in unexplained variance in 
LOS across hospitals, after controlling for all other characteristics. Figure 2.1.2 shows 
these random effects and their respective 95% confidence intervals for the 41 hospitals 
analysed. 
 
Figure 2.1.2. Random effects and 95% Confidence Intervals for each hospital.  
 
For the period 2009–2014, most hospitals had an estimated random effect closer to the 
mean value (one). However, two hospitals (40 and 41) showed a large positive effect, 




The constant decline in HIV-related hospitalizations during the period 2009–2014 is in 
line with what was observed in other studies [47]. In fact, the decrease in HIV incidence 
observed in Portugal suggests success in controlling the HIV epidemics in Portugal, 
following the worldwide trend [48]. In our analysis, most HIV patients (71.8%) 
hospitalized during the study period were men, which can be explained by the fact that, 
like in the rest of Europe, most of HIV patients in Portugal are men [49]. Therefore, 
estimated LOS was lower for female patients and longer for male patients. Over the study 
period, the median age of HIV patients hospitalized increased slightly, suggesting that 







PLHIV are living longer, as demonstrated by other studies [47]. While urgent admissions 
have decreased steadily between 2009 and 2014 (-37.7%) – having dropped by 10.4% 
between 2009 and 2011 and by 26.2% between 2012 and 2014 – elective admissions 
increased until 2012 (+36.2%) but declined in the following 2 years (-41.3%). 
This study specifies a hierarchical Poisson regression to model HIV/AIDS LOS in 
Portuguese public hospitals. The estimated LOS of HIV/AIDS patients hospitalized in 
each year between 2010 and 2014 was significantly shorter than those hospitalized in 
2009. A recent study carried out in Portugal analysed all in-patient stays at all Portuguese 
NHS hospitals over the 2001–2012 period and found that the volume of in-patient stays, 
particularly non-elective stays, increased significantly, while the length of stay has 
become shorter and elective admissions have decreased [1]. Although our analysis 
included HIV/AIDS patients only, and the study period was different, we found similar 
results regarding the shorter LOS and the decrease of elective admissions. 
The decrease of LOS for HIV/AIDS hospitalizations found in our analysis could be 
explained by two different hypotheses. The first one is that the EFAP measures might 
have induced efficiency gains, improving response from healthcare units. In contrast, the 
EFAP measures might have reduced quality of care provided in hospitals, with a reduction 
of the number of in-patient beds and increasing pressure to reduce LOS and cut costs [50]. 
However, our findings are not sufficient to support one hypothesis over another and 
further research is needed. Our results showed that the hospital’s financial situation 
affected HIV/AIDS patients’ hospitalizations: a greater current ratio decreased estimated 
LOS. This finding is supported by other studies that show a strong negative association 
between LOS and hospitals’ operating margins [51]. Long hospitalizations consume 
many hospital resources and are, therefore, associated with increasing costs. The year 
dummies remained statistically significant in Model 2, even after introducing the variable 
measuring hospitals’ current status. The fact that the annual decrease in LOS for 
HIV/AIDS patients was not explained by the hospitals’ current status, suggests a 
generalised pressure to reduce costs not fully related with the hospitals’ financial 
situation. By 2011, NHS hospitals were facing a severe financial situation, with the total 
amount of arrears (accounts payable to domestic suppliers past due date by 90 days) 








programme (EFAP), a number of cost-containment measures and actions aimed at 
increasing efficiency in the health sector were implemented between 2012 and 2014. The 
Memorandum of Understanding clearly established the reduction of hospitals’ operating 
costs as a priority, which is the reason why NHS hospitals were under continuous pressure 
to cut costs during the period of the EFAP. Our findings suggest that this was an important 
contributor for the decrease of LOS among HIV/AIDS patients. 
While patients’ age is not statistically significant at the 5% level, when adjusting for other 
factors the estimated LOS was significantly lower for patients who died, suggesting that 
mortality occurs mostly at an early stage of hospitalization. This means that there is high 
mortality among those patients who are admitted at the hospital in more severe stages of 
AIDS-related illness, as supported by other studies [42]. Both the number of secondary 
diagnoses and the number of procedures significantly increase LOS, suggesting longer 
hospitalizations. A greater number of diagnoses or procedures suggests a more severe 
condition of the patient admitted and therefore leads to a delayed discharge [52]. Also, 
estimated LOS was longer for patients who had HIV/AIDS as principal diagnosis, 
suggesting that those patients are admitted in a more severe condition and are therefore 
more likely to need a longer hospitalization. 
The estimated LOS for HIV/AIDS patients was shorter for urgent admissions. It is 
important to highlight that, in Portugal, urgent admissions do not necessarily reflect 
emergency situations, as noted by previous studies [42]. Due to difficulties in accessing 
lower levels of care, it is not uncommon that patients seek assistance directly at a hospital 
emergency service, thus bypassing primary healthcare [53]. 
The variable measuring the effect of hospital mergers into hospital centres on estimated 
LOS for HIV/AIDS patients was not statistically significant in Model 2, after introducing 
the variable current status. Mergers can be a way of eliminating excess capacity and 
cutting costs, and additionally they can address performance issues for particular units or 
services. Hospital mergers in Portugal began in 1999 but were intensified in recent years, 
as a result of the economic and financial adjustment programme (EFAP) [4]. By 
concentrating within the same administration hospitals operating in the same geographic 
area and offering the same services, the aim was to increase efficiency and promote 
economies of scale. However, results from our study suggest the opposite, considering 







LOS as an indicator of hospital efficiency. Regarding recent mergers, the literature 
suggests that there are economies of scale and scope to explore further, but only mergers 
of relatively small and similar hospitals have been successful [54]. In fact, hospital 
mergers in Portugal did not achieve the expected efficiency gains due to the heterogeneity 
and geographical dispersion of many hospitals. As a result, despite being under the same 
administration, many hospitals kept the same practices as they had prior to being merged 
with other hospitals. 
Estimated hospital random effects suggest differences amongst hospitals which also 
require the need for further research. These effects which acknowledge unexplained 
factors that are nonetheless important, can be interpreted as differences in hospital 
efficiency, after controlling for all relevant factors. Hospitals 40 and 41 showed a positive 
effect, extending LOS for HIV/AIDS patients. Hospital 40 corresponds to a hospital 
centre in northern Portugal, geographically disperse and with no differentiated services, 
while hospital 41 is a large hospital in the Lisbon metropolitan area, offering more 
differentiated services. 
Our study provides an analysis of relevant factors related to LOS among HIV/AIDS 
hospitalizations between 2009 and 2014 in Portugal. However, it is important to note that 
healthcare-associated infections have a high prevalence in Portugal – overall prevalence 
rate of 10.5% in 2013 [55] – and are responsible for greater medical costs, longer LOS, 
and an increase in mortality rates. Our analysis did not include other types of pneumonia 
or urinary tract infections, which are major complications from nosocomial infections, as 
covariates, but the findings for pneumocystis pneumonia should prompt further research. 
Although the EFAP, in place between May 2011 and May 2014, and the severe economic 
recession in Portugal brought important social and economic consequences in Portugal, 
the interpretation of our findings must be carried out with caution. Between 2012 and 
2014, Portugal also witnessed changes in the National Network of Long Term Care which 
was expanded and might have influenced the overall reduction in LOS among patients in 
Portuguese NHS hospitals. Our analysis did not address the potential impact of that 
support network. In fact, an aspect of the whole system performance that is ignored in 








system. For instance, it could be the case that the decrease of LOS is being secured at the 
expense of heavy workloads for rehabilitative and primary care services [56]. 
This study used comprehensive discharge data compiled in mainland Portugal, and these 
findings are more generalisable than results based on data from a single hospital. 
However, this study has limitations, due to the nature of the data [57]. Firstly, there are 
limitations regarding the retrospective collection of data for administrative purposes, 
which can allow for mistakes in recording information and/or variability of coding among 
hospitals. Secondly, the DRG database has very limited clinical information, which would 
have been important to better understand the clinical profile of HIV/AIDS patients (e.g. 
the number of years the patient is engaged in care, viral load, CD4 cell count, ART 
regime). To track the long-term outcomes and quality of care, further research is needed 
on the information system specially implemented in NHS hospitals in Portugal to capture 
these important components of HIV-related care (SI.VIDA). Also, in this analysis, the 
number of secondary diagnosis was used as a proxy of the number of co-morbidities, and 
therefore as an indicator of the patient’s condition. However, this approach reveals 
nothing about the severity of each secondary diagnosis and does not measure their 
severity. Future research could consider the use of Elixhauser Comorbidity Index or 
Charlson Comorbidity Index [58,59], which have been widely utilised by health 
researchers to measure burden of disease and case mix. 
The fact that hospital institutions were coded in the DRG database according to the 
hospital centre to which they belong may have prevented a more detailed analysis of the 
data. Although a dummy variable was considered to capture the aggregation of hospitals 
into hospital centres, it would be interesting to explore, within a single hospital centre, 
differences among institutions regarding risk-adjusted LOS. 
Finally, the selected study period is also a limitation of this analysis. Although the main 
objective was to measure the impact of the EFAP on hospital in-patient care for PLHIV, 
the analysis over a longer period would have allowed us to better identify and measure 
the austerity effect from the long-term trends in LOS. 
 
 








The subject of the impacts of the economic crisis on the health of the population has been 
the focus of many studies in recent years [5-7]. Health policy research in this field poses 
important methodological challenges as it is often difficult to distinguish austerity 
measures from the overall economic crisis and its impact on health systems. Therefore, 
the model presented in this study aims to contribute to the analysis of the effects of the 
economic and financial adjustment programme on a particular group of patients. 
This study presents a hierarchical Poisson model to analyse LOS among HIV/AIDS 
patients in Portuguese public hospitals. A number of variables (HIV/AIDS as principal 
diagnosis, number of secondary diagnoses, number of procedures and tuberculosis) were 
found to increase LOS, while others (in-hospital mortality, urgent 
admission, Pneumocystis pneumonia and hepatitis C) contributed to the decrease of LOS. 
Our findings also show that LOS decreased during the study period, and elective 
admissions decreased after 2012. Our findings also showed that hospital’s current ratio 
was found to decrease LOS, meaning that the better the financial situation, the lower the 
LOS for HIV/AIDS patients. With regard to HIV/AIDS hospitalizations, two of the 
analysed hospitals showed a large positive effect, extending patients’ length of stay. 
These findings are a contribution to the study of the effects of the austerity measures 
implemented in Portugal between 2011 and 2014 in hospital care provision to a particular 
vulnerable group of patients. Our analysis suggests that the measures in place to cut costs 
and increase efficiency in public hospitals contributed to the decrease of HIV/AIDS 
patients’ LOS. 
Results from this analysis demonstrate the need to further study this issue in order to 
better understand the effects of the EFAP on health and health care. Additionally, it would 
be important to implement measures to efficiently monitor health care delivery, 
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2.2.  Preventing HIV under financial constraints: the 2011-12 reform of 
the Portuguese HIV/AIDS Programme 
 
2.2.1. Background 
Since the first case of HIV infection in 1983, Portugal has recorded a total number of 
57,913 HIV cases by 2017 [1]. In 2017, Portugal recorded the third highest HIV incidence 
rate(12.0 new HIV diagnoses per 100,000 population – not adjusted for notification delay) 
among EU/EEA countries, after Latvia (19.0) and Estonia (16.6) [2].  
As in other countries, national response to HIV in Portugal started as a vertical policy 
programme. The country’s national response to HIV goes back to 1985, when the first 
AIDS Working Group was established [3]; in that same year, a national notification 
system of HIV infection was enacted, which made it possible to compare the Portuguese 
epidemic trajectory with other European countries. Antiretroviral treatment (ART) has 
been fully covered by the universal National Health Service (NHS) and, since 2001, 
foreign citizens living in Portugal have legally the same access to NHS services, including 
ART, and the same standard of care as national citizens. 
Created in 1990 to replace the AIDS Working Group, the National Commission for the 
Fight Against AIDS (Comissão Nacional de Luta Contra a SIDA) became the official 
body responsible for coordinating the national HIV response, focusing on prevention, 
education, research and surveillance [4]. Since the establishment of this group, the 
country has implemented several policies on HIV, approved new legislation, and 
developed and implemented new programmes. In 2002, the network of Voluntary Testing 
and Counselling Centres (Centros de Aconselhamento e Deteção, CAD) was launched, 
aimed at delivering services for voluntary, anonymous, confidential and free HIV testing, 
as well as pre- and post-counselling.  
In 2005, the National Commission Against AIDS was abolished and the National 
Coordination for HIV/AIDS Infection was created to replace it, within the newly created 
High-Commissariat for Health [5,6]. This body was intended to provide technical support 
to policymaking and strategic planning, as well as to produce the National Health Plan 








coordination of the four vertical programmes: Cardiovascular diseases, Oncologic 
diseases, Mental health, and HIV/AIDS [7]. The National Coordination for HIV/AIDS 
Infection was responsible for HIV/AIDS surveillance, leading an integrated information 
system created for that purpose, as well as for the acquisition and distribution of 
prevention materials, including syringes, condoms and rapid tests. HIV/AIDS is a 
mandatory notifiable disease in Portugal since 2005 [8], and the national database of all 
HIV cases reported in Portugal is maintained by the National Institute of Health (INSA, 
Instituto Nacional de Saúde Doutor Ricardo Jorge), which is the national reference 
laboratory of the Ministry of Health.  
The aim of this paper is to describe and discuss the reform of the HIV/AIDS Programme 
in Portugal that took place in 2011-12,in the context of severe financial constraints and 
austerity measures imposed in the country. Results from this analysis are relevant to 
illustrate how health reforms can be implemented during difficult economic contexts 
taking into account effectiveness and health outcomes.  
 
2.2.2. Content of the reform: the National Programme for HIV/AIDS Infection 
The High-Commissariat for Health was abolished in 2011, in the context of a 
restructuring of the central services of the Ministry of Health [9]. The global financial 
and economic crisis in 2008 forced Portugal to request a financial bailout from the 
European Commission, the International Monetary Fund and the European Central Bank 
[10-12]. This new financial environment required the containment of costs and 
improvements in efficiency within all services of the Ministry of Health. 
Following the abolition of the High Commissariat for Health, the Directorate-General of 
Health (DGS, Direção-Geral da Saúde ) saw its competencies reinforced. This body 
became responsible for all vertical programmes and for the National Health Plan [9,13]. 
Thus, the National Coordination for HIV/AIDS Infection was succeeded by the National 
Programme for HIV/AIDS Infection, as part of a set of nine priority health programmes, 
including diabetes, cerebro-cardiovascular diseases, oncological diseases, mental health, 
tobacco control, respiratory diseases, healthy nutrition, prevention and control of 
antimicrobial resistance and infections, and HIV/AIDS [13,14]. Each priority health 
programme is organised in accordance with the national health strategies, as included in 







the new National Health Plan (2012-2016, extended to 2020), and has a four-year term. 
More recently, three additional priority health programmes were established: viral 
hepatitis, physical activity, and tuberculosis [14].   
The strategic guidelines followed by the National Programme for HIV/AIDS Infection 
for the term 2012-2016 were aligned with the UNAIDS goals, and were informed from 
inputs by different stakeholders, including patients’ associations and civil society 
organisations [15]. The goals to be achieved by the end of 2016 were [15]: 
• Decrease new HIV Infections in Portugal by 25%; 
• Decrease from 65% to 35% late HIV diagnosis (CD4 < 350mm3); 
• Decrease new AIDS cases by 50%; 
• Decrease AIDS-related deaths by 50%; 
• Increase to 95% the proportion of individuals reporting condom use in casual sex;  
• Eliminate mother-to-child transmission of HIV.  
In summary, the main purpose of the reform was to integrate national HIV response 
among the set of priority health programmes targeting main diseases and risk factors in 
the Portuguese population. This reform also follows the increasing shift in the global 
response to the HIV epidemic towards an integrated approach that strengthens health 
systems and improves all health outcomes while striving towards the goal of universal 
access to HIV prevention and treatment [16]. Accordingly, 2010 WHO guidelines for 
HIV treatment presented a public health approach and called for an integration of HIV 
services in the countries’ health systems [16]. In general terms, the new National 
Programme for HIV/AIDS Infection kept the same approach to HIV prevention strategies 
initiated by the National Coordination, but experienced important budgetary and 
organizational changes. 
 
2.2.3. Process of the reform 
The restructuring of the national HIV Programme, following the abolition of the National 
Coordination for HIV/AIDS Infection, was a challenging process. By 2012, the 
Portuguese Government adopted a series of austerity measures, with severe cuts in public 








the new National Programme for HIV/AIDS Infection was forced to rearrange its internal 
functioning and to take actions to improve the efficiency of available resources [17]. The 
National Coordination for HIV/AIDS Infection was followed by a programme with fewer 
human resources which still had to deal with severe demands for public health.  
Although main stakeholders were neutral regarding this reform, civil society 
organisations were strongly opposed to these changes due to a loss in the programme’s 
autonomy, increased bureaucracy and reduced funds available. 
From 2011-2012, there was a delay in integrating the HIV/AIDS Programme’s budget in 
the Directorate-General of Health, which resulted in successive delays in paying suppliers 
and acquiring preventive materials (male and female condoms). The implementation in 
all public hospitals of the new electronic information system to follow-up HIV patients 
also suffered significant delays. Finally, by the end of 2012, the National Association of 
Pharmacies decided to terminate the agreement in the context of the Syringe Exchange 
Programme, with effect from 1 January 2013 [17].  
 
2.2.4. Outcomes of the reform 
Portugal has had a significant decline in new HIV and AIDS diagnoses in the past decade 
(Fig. 2.2.1). Decrease in new HIV diagnosis was more significant in persons infected by 
heterosexual transmission, people who inject drugs (PWID) and mother-to-child 
transmission (MTCT), while new HIV diagnoses in men who have sex with men (MSM) 
show a stable trend [1]. AIDS-related deaths have also steadily decreased in the past 10 
years in Portugal (Fig. 2.1.1). Since 2011, the annual number of deaths in people infected 
heterosexually is higher than in PWID [1]. 
For the period 2009-2018, we reviewed the outcomes of core HIV prevention 
programmes managed by the National Programme for HIV/AIDS Infection: financial 
support to private non-for-profit organisations, the syringe exchange programme, HIV 
rapid testing, and the distribution of preventive materials. These programmes correspond 


























Source: DGS/INSA (as of 31 Dec 2018) 
Figure 2.2.1. Number of new HIV and AIDS cases, and AIDS-related deaths, Portugal,  
2009-2017. 
 
2.2.4.1.  New rules for financial support to private non-for-profit organisations 
In 2002, the ADIS/SIDA Programme (Apoio Desenvolvimento Intervenção SIDA) 
established the rules for the financial support from the National Commission for the Fight 
Against AIDS to projects and actions carried out by civil society organizations dedicated 
to the response to HIV/AIDS in Portugal. In 2006, the Portuguese Government approved 
legislation to regulate the allocation of funding to private non-for-profit organizations 
[18]. Following the new legislation, in 2009 the amount dedicated to the ADIS 
Programme was EUR 9.5 million for a 4-year period: EUR 8.4 million to pluriannual 
projects funded in 2008 and 2009, and EUR 1.1 million to fund new projects to be 
implemented from 2010 onwards [19,20]. In 2010, the total amount dedicated to the ADIS 
Programme was EUR 4.0 million, and the National Coordination for HIV/AIDS Infection 
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2011, the amount dedicated to the ADIS Programme was EUR 9.0 million for a 4-year 
period [23]. This was the final year of both the ADIS programme and the National 
Coordination for HIV/AIDS Infection.  
Financial support to private non-for-profit organisations by the Ministry of Health was 
newly regulated in 2013, and the Integrated System for Health Financial Support 
Programmes (Sistema Integrado de Programas de Apoio Financeiro em Saúde, SIPAF) 
was created [24]. By the end of 2013, organisations were able to request funding for their 
projects according to the new rules. The amount dedicated by the Portuguese Government 
for that purpose was EUR 1 million, which was to be spent in 2014 (exclusively for 
HIV/AIDS projects) [25]. For 2015, the government established an amount of EUR 2.3 
million for pluriannual programmes (2 years) and EUR 75,000 for specific programmes 
to fund projects in the framework of the National Health Plan and all Priority Health 
Programmes (including the HIV/AIDS Programme) [26]. For 2016, EUR 2 million were 
dedicated to fund HIV/AIDS projects [27], and, for 2017, the Portuguese Government 
allocated EUR 2.8 million to fund projects on HIV/AIDS, diabetes, mental health and 
healthy nutrition, for the period of one year [28].  
Under the new funding rules, the National Programme for HIV/AIDS Infection targeted 
the expansion of HIV testing as a strategic priority, funding non-governmental and 
community-based organisations (NGOs/CBOs) across the country to provide HIV testing 
services. Besides retaining funding for previously approved projects under the ADIS 
Programme, funding for new projects was available, although the annual expenditure with 
financial support to NGOs/CBOs was initially for a shorter period than before. More 
recently, in 2018, the Portuguese Government allocated EUR 3.7 million to fund projects 
carried out by private non-for-profit organisations during a 2 year-period [29].  
 
2.2.4.2.  Reduction of costs with the Syringe Exchange Programme 
Pharmacies have been key partners in the network of harm reduction services provided 
to PWID. The Portuguese Syringe Exchange Programme (SEP) was established in 
October 1993 as a partnership between the Ministry of Health and the National 
Association of Pharmacies (Associação Nacional das Farmácias), with the collaboration 
of wholesalers and municipalities. Pharmacies distribute free kits, containing two sterile 







syringes and needles, two swabs, two filters, two ampoules of distilled water, two 
recipients for the preparation of drugs, two citric acid sachets, and one condom [30]. The 
participation by pharmacies is voluntary and no fee-for-service is charged. The National 
Programme for HIV/AIDS Infection funds the production and distribution of injecting 
equipment, as well as the collection and destruction of sharp waste generated. Between 
1993 and 2017, over 56 million syringes were distributed.  
The SEP was operated exclusively in community pharmacies between 1993 and 1998, 
but after 1999, NGOs/CBOs also began participating in the distribution and collection of 
kits. Since 2009, the number of syringes collected or exchanged at community pharmacies 
has been decreasing, as NGOs/CBOs became the main drivers of distribution. Between 
2009 and 2012, the number of syringes distributed decreased by 60% (Fig. 2.2.2). This 
was due to a change in the drug use pattern, with a gradual reduction in injecting drug 
use.  
When the agreement with the National Association of Pharmacies was cancelled in 2012, 
SEP was transferred to Public Health Units, at Primary Health Care [31]. Additionally, 
NGOs/CBOs would operate the distribution of kits in the streets, including night 
schedules. In 2013 the number of syringes collected or exchanged decreased by 14% 
(Figure 2.2.2), and only 3% of the syringes were collected/exchanged at Public Health 
Units. In July 2014, a new agreement between the Ministry of Health and the National 
Association of Pharmacies was signed, and since January 2015 the SEP has been 
implemented again at community pharmacies. As a result, since 2015, there has been an 
upward trend in the number of syringe kits distributed (Figure 2.2.2).   
In terms of SEP costs, there was a reduction by 68% between 2011 and 2012, but that 
trend was reversed in 2014 (Figure 2.2.2). Overall, between 2009 and 2018, SEP costs 
were reduced by 30%. This development is explained by the centralisation of purchase of 
SEP kits. In fact, the purchase of SEP kits meets the programme needs for long periods 
and explains the variations in annual total expenditure. However, in contrast to what was 
observed in Greece [32], the number of new HIV cases in PWID in Portugal continued 









Source: National Programme for HIV/AIDS Infection/DGS 
Figure 2.2.2. Number of syringes distributed/exchanged and total expenditure, 2009-2018.  
 
 
2.2.4.3.  Greater investment in community-based HIV testing 
Typically, rapid HIV testing was provided by the Portuguese National Health Service at 
HIV Testing and Counselling Centres (CAD, Centros de Aconselhamento e Detecção). 
There were 20 active HIV Testing and Counselling Centres in 2006, but two of them were 
shut down in 2007, and one more closed its doors in 2012. This happened because of low 
demand as new community responses became available. HIV testing services were 
gradually offered by proximity structures operated by NGOs/CBOs, as these structures 
were effective in reaching most-at-risk populations, particularly key populations in the 
large urban areas of Lisbon and Oporto. Co-funded by the National Coordination for HIV 
Infection, the first community testing centre targeting men who have sex with men opened 
its doors in Lisbon in 2011. In the following years, changes in prioritisation of funding 
by the National Programme for HIV/AIDS Infection and the organisation of a national 
network of testing projects operated by NGOs/CBOs, made it possible to expand not only 






































Syringes distributed/exchanged Total expenditure








Source: National Programme for HIV/AIDS Infection/DGS 
Notes:  
1) Total expenditure includes rapid testing for hepatitis B, hepatis C and syphilis provided by NGOs/CBOs, according 
to their Terms of Reference.  
2) Reactivity rates express the rate of HIV rapid tests whose result was reactive for HIV antibodies; a confirmatory test 
is needed to verify a reactive result and diagnose HIV infection.  
3) HIV tests prescribed by doctors in primary health care or hospital settings are not included here, as these tests are 
not funded by the National Programme for HIV/AIDS Infection.  
Figure 2.2.3. Number of HIV rapid tests by type of service (with respective reactivity 
rates), and total expenditure, 2009-2018. 
 
From 2013 onwards, the role of NGOs/CBOs and primary health care units in providing 
HIV rapid testing became more evident. Thus, the number of HIV tests at HIV Testing 
and Counselling Centres therefore decreased steadily, while the number of HIV tests at 
NGOs/CBOs since 2014 have been registering a remarkable increase, exceeding those 
performed at HIV Testing and Counselling Centres in 2016 and 2017 (Figure 2.2.3). 





































HIV Testing & Counselling centres NGOs/CBOs Primary health care (NHS) Total expenditure
0.91% 0.93% 1.06% 0.91% 0.98% 0.95% 1.06% 1.04% 1.19% 1.29% 
2.37% 1.68% 












by the Regional Health Administration and not by the HIV Programme, which is why the 
number of HIV tests in NGOs/CBOs funded by the Programme has decreased (Figure 
2.2.3).  The number of HIV tests in primary health care was initially residual, but between 
2016 and 2018 the number of HIV tests has had a 4-fold increase (Figure 2.2.3). The 
number of HIV rapid tests in all settings increased by 61% between 2013 and 2018, 
reaching 34,458 in 2018.  
After a period (2009-2013) with little variation in expenditure, total expenditure on HIV 
rapid testing has shown a remarkable increase after 2013, as the HIV Programme started 
funding rapid HIV testing in other settings such as NGOs/CBOs and primary healthcare 
units (Figure 2.2.3). It is important to note that the total expenditure on HIV rapid tests 
is in part related to acquiring and distributing the testing kits, which can be used according 
to the demand in each setting and taking into account their expiration date.  
Reactivity rates had a great variation according to the testing setting (Figure 2.2.3): 
NGOs/CBOs have the highest reactivity rates due to their proximity services targeted to 
most-at-risk key populations, which those organisations are more effective reaching.  
 
2.2.4.4.  Increased spending in preventive materials 
The National Programme for HIV/AIDS Infection is responsible for the acquisition of 
preventive materials to be distributed within the Portuguese National Health Service, both 
in HIV Testing and Counselling Centres and in primary health care. It is also responsible 
for acquiring preventive materials to be distributed by NGOs/CBOs working on HIV 
prevention. Preventive materials include male and female condoms, and also lubricant.  
The number of male condoms distributed declined dramatically between 2009 and 2012, 
registering a steady increase ever since this period, while the number of female condoms 
shows a decreasing trend since 2014 (Figure 2.2.4). Data shows a 24% increase in 
expenditure on preventive materials from 2009 to 2018. The variations in total 
expenditure during the 10-year period are explained by the centralisation of purchase and 
the validity of preventive materials. Thus, peaks in expenditure correspond to the 
acquisition of a very large amount of preventive materials for distribution during the 
subsequent months, based on demand and needs (Figure 2.2.4).  







Despite being currently in smaller number than in the beginning of the selected period, 
the decrease in the number condoms distributed does not seem to have impacted the 
country’s HIV epidemic, at least for those who are infected heterosexually.  
 
 
Source: National Programme for HIV/AIDS Infection/DGS 
Note: Besides male and female condoms, total expenditure includes lubricant.            
Figure 2.2.4. Number of male and female condoms distributed and total cost on 
preventive materials, 2009-2018. 
 
2.2.5. Discussion 
The reforms of Portugal’s vertical programmes, including the HIV/AIDS Programme, 
have been a challenging process that occurred during a difficult financial and economical 
context in the country. This reform was an organisational response from the Ministry of 
Health as a consequence to the extinction of the High Commissariat for Health. This 
event, that was coincident with the new National Health Plan (2012-2016), was an 
opportunity to organise priority health programmes targeting particular risk factors and 
diseases in the population. The reform of the HIV/AIDS Programme also followed the 












































The HIV/AIDS Programme reform must be analysed from two different perspectives. 
One is the move towards an integration of HIV response in other settings of the 
Portuguese National Health Service. HIV Counselling and Testing Centres are no longer 
the main providers of rapid HIV testing to the population, as rapid testing became widely 
available in primary care units and NGOs/CBOs, through HIV/AIDS Programme 
funding. The distribution of preventive materials and syringe kits have for a long time 
been assured by structures closer to the community such as NGOs/CBOs and pharmacies. 
The other perspective is the economic and financial crisis that affected Portugal. After 
the reform, the new National Programme for HIV/AIDS Infection operated with less 
financial and human resources than its predecessor.  
Although the main purpose of the reform was to resize the programme and introduce 
organisational changes to make it more efficient, transitory financial constraints in 2012 
and 2013 imposed important difficulties in running the Programme’s main activities. 
Nevertheless, in general terms, the National Programme for HIV/AIDS Infection was able 
to improve its efficiency and sustain its core activities. Since the reform was 
implemented, Portugal was able to reduce new HIV infections by 35%, new AIDS cases 
by 60% and AIDS-related deaths by 50%.  
The most important feature of this reform was the definition of clear prioritisation of 
resources. Since the HIV/AIDS Programme has less resources than its predecessor, 
resources were prioritised for the expansion of HIV testing. That was made possible 
through strategic partnerships with NGOs/CBOs, which are more effective in reaching 
the most-at-risk populations. Other studies confirm that prioritising screening in higher-
risk populations and geographic settings is cost-effective [33].  
Despite the initial difficulties faced by the new National Programme for HIV/AIDS 
Infection, new HIV diagnosis continued to decline as HIV testing was being expanded. It 
is important to note that access to antiretroviral therapy (ART) for people living with HIV 
in free in Portugal and it is an important factor contributing to halt the epidemics. 
Although the National Programme for HIV/AIDS Infection does not manage the 
provision of ART, it played an important role for the adoption, in 2015, of WHO’s new 
recommendations on HIV treatment: treat all, meaning that everyone tested positive for 
HIV should be linked to ART irrespective of their clinical condition [34].  







Finally, the reform of the Portuguese HIV/AIDS Programme can also be placed in the 
context of the European response to HIV. Some authors argue that the economic crisis of 
2008 forced a shift from a human rights approach to HIV/AIDS to an increased focus on 
containment, efficiency, and cost reduction [35]. However, despite the economic crisis, 
Portugal’s response to HIV has kept an emphasis on human rights, including the reduction 
of stigma and discrimination, as well as assuring all PLHIV timely access HIV care. 
 
2.2.6. Conclusion 
The National Programme for HIV/AIDS Infection has identified core challenges for the 
near future, namely to expand access to pre-exposure prophylaxis (PrEP) to individuals 
most at risk of HIV infection; to improve electronic information systems for better 
information; to improve access and enhance adherence to antiretroviral therapy; to 
evaluate and possibly expand dispensation of antiretroviral therapy in community 
pharmacies (being piloted since 2017); and to decrease late diagnosis by continuing to 
promote access to quality HIV testing services – including rapid tests for HIV, and 
hepatitis B and C in community pharmacies – and by making HIV self-testing available 
in community pharmacies [36], which happened in October 2019 [37]. 
Portugal has successfully reduced the number of new HIV infections in the past decade, 
while the country was struggling with a severe economic crisis. The reform of the 
HIV/AIDS Programme promoted efficiency and important partnerships with 
NGOs/CBOs, which were crucial to keep the country’s response towards HIV during 
those difficult times. In this sense, results from this analysis are important to illustrate 
how health reforms can be successfully implemented during difficult economic contexts. 
Adopting and expanding innovative preventive tools, expanding HIV testing, and 
improving access and adherence to HIV care will be pivotal actions to accelerate the 
reduction of HIV epidemics in the country. Keeping ties with civil society organizations 
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2.3.  Trends in HIV surveillance data in Portugal, 2005-2017: patterns 
observed among native and foreign-born cases 
 
2.3.1. Introduction 
Human immunodeficiency virus (HIV) transmission remains a significant public health 
challenge in Europe, affecting more than 2 million people [1,2]. With a rate of 12.7 cases 
per 100,000 population in 2016, Portugal was among the countries in the European Union 
and European Economic Area (EU/EEA) with the highest incidence rate of HIV, 
following Latvia (18.5), Estonia (17.4) and Malta (14.5) [2]. 
Portugal has a concentrated HIV epidemic with specific characteristics, given its 
historical and cultural bounds with Sub-Saharan Africa and Brazil [3]. After reaching a 
peak in 1999, when the epidemic was mainly driven by cases among people who inject 
drugs (PWID), the number of both new HIV and AIDS diagnoses in Portugal has been 
decreasing steadily. Heterosexual contacts are the most frequent mode of HIV 
transmission identified among all cases diagnosed during last decade; however, sex 
between men recently exceeded heterosexual transmission amongst male cases [4].   
The aim of our study was to analyse Portuguese HIV/AIDS surveillance data for the years 
2005 to 2017, in order to better understand transmission patterns and identify key 
populations for whom prevention efforts can be intensified.  
 
2.3.2. Methods 
2.3.2.1. Data source 
We used data from the national HIV and acquired immunodeficiency syndrome (AIDS) 
registry database, collected as part of HIV/AIDS surveillance in Portugal. A dedicated 
surveillance system was set up in 1985 on a clinician voluntary case report basis; in 2005, 
HIV/AIDS became a mandatory communicable disease [5]. Since 2015, mandatory 
notification of transmissible diseases, including HIV/AIDS, is done exclusively by an 
electronic platform [6]. The national registry database of all HIV and AIDS cases reported in 
Portugal is maintained by the National Institute of Health (INSA, Instituto Nacional de Saúde 








We included all new HIV and AIDS cases diagnosed between 1 January 2005 and 31 
December 2017, notified until 31 December 2018. Data was anonymised and variables 
extracted were the following: year of diagnosis (HIV infection and AIDS), gender, age at 
diagnosis (age-group), country of birth, mode of transmission, country of probable 
acquisition of HIV infection, stage at diagnosis and CD4 count at first evaluation. 
 
2.3.2.2. Definitions 
For this analysis we defined foreign-born cases as cases born outside Portugal, 
irrespective of their nationality, while native-born cases were defined as cases born in 
Portugal. A late HIV diagnosis was defined as having a CD4+ T-cell count below 350 
cells/mm3 at HIV diagnosis [7]. 
 
2.3.2.3. Statistical analysis 
Descriptive analysis were conducted on trends in new HIV and AIDS diagnoses, and late 
HIV diagnoses. Linear regression models were used to test for trends, whereby the 
significance level was set at 0.05. Overall proportions of new HIV diagnoses according 
to age group, route of transmission and probable place of acquisition of HIV infection 
were also calculated. Statistical significance for differences between proportions was 
tested at a significance of 0.05. All statistical analyses were conducted using SPSS 25.0. 
 
2.3.3. Results 
Between 2005 and 2017, 23,468 people were newly diagnosed with HIV infection in 
Portugal. The majority of cases (69.0%) were men and most (29.7%) were 30-39 years 
old. A total of 14,007 cases (59.7%) were attributed to heterosexual contact, 5,932 
(25.3%) to men who have sex with men (MSM), 2,955 (12.6%) to injecting drug use, and 
185 (0.8%) to other routes of transmission. The transmission mode was not reported or 
unknown in 389 cases (1.7%). Between 2005 and 2017, 29.7% (n=6,972) of newly 
diagnosed HIV cases in Portugal were foreign-born; the place of birth was not recorded 
in 1.2% (n=290) of cases. The five top foreign countries of birth by absolute numbers 







were all Portuguese speaking countries: Guinea-Bissau (n=1,627), Brazil (n=1,499), 
Angola (n=1,175), Cape Verde (n=889), and Mozambique (n=490). 
 
2.3.3.1. Trends in new HIV diagnoses in Portugal, 2005-2017 
Between 2005 and 2017, the number of new HIV diagnoses attributed to heterosexual 
transmission and injecting drug use decreased significantly both in foreign and native-
born people (p value for trend < 0.001 in all groups), while the number of diagnoses in 
MSM shows an non-significant increasing trend, both in native and foreign cases (p value 
for trend 0.06 and 0.09, respectively) (Figure 2.3.1). Unlike native-born cases, the 
number of new HIV infections is systematically higher among foreign-born women with 
heterosexual transmission when comparing to foreign-born heterosexual males. In 
heterosexual native-born cases, male-to-female ratio was 1.4, while in heterosexual 
foreign-born cases was 0.8.  
 
 
Source: DGS/INSA  
Note: Cases with unknown place of birth, unknown route of transmission and other routes of transmission 
were excluded from data presented here. 
Figure 2.3.1. Number of new HIV diagnoses with known route of transmission, by place 
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Age was reported in 23,439 cases, of which 22.8% were 50 years or older. While most 
foreign-born men infected heterosexually were 40-49 years old (33.4%), most native-born 
men infected by heterosexual route were 50 years or older (42.0%), a proportion 
significantly higher than in any other group (p<0.001) (Figure 2.3.2). In women infected 
heterosexually, most foreign-born were 30-39 years old (32.6%) and most native-born 
were 50 years or older (29.6%). In MSM, most native and foreign-born cases were 20-29 
years old (39.0% and 36.1%, respectively), while in PWID were aged 30-39 years old 




Note: The category “All cases” includes 22,604 cases for whom place of birth and route of transmission 
was known and an additional 835 cases for whom place of birth was unknown and/or route of transmission 
was unknown or corresponded to other routes of transmission. 
Figure 2.3.2. Proportion of new HIV diagnoses by age group at diagnosis, by place of 
birth and main route of transmission, Portugal, 2005-2017 (n = 23,439). 
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2.3.3.2. Trends in AIDS diagnoses in Portugal, 2005-2017 
Between 2005 and 2017, 8,071 people were diagnosed AIDS in Portugal. A total of 4,454 
cases (55.2%) were attributed to heterosexual contact, 4,440 (30.2%) to injecting drug 
use, 1,009 (12.5%) to MSM, and 44 (0.5%) to other routes of transmission. The 
transmission mode was not reported or unknown in 124 cases (1.5%).  
During the study period, 24.3% (n=1,959) of new AIDS cases diagnosed in Portugal were 
foreign-born, while 74.9% (n=6,047) were born in Portugal. The place of birth was not 
recorded in 0.8% of cases. The number of AIDS cases has significantly decreased in all 
transmission groups (p value for trend < 0.001), except in foreign-born women infected 
by heterosexual route and foreign-born MSM (p value for trend 0.175 and 0.381, 
respectively) (Figure 2.3.3). In native-born cases with heterosexual route of transmission, 




Note: Cases with unknown place of birth, unknown route of transmission and other routes of transmission 
were excluded from data presented here. 
Figure 2.3.3. Number of AIDS diagnoses, by place of birth and main route of 
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2.3.3.3. Late diagnosis in Portugal, 2005-2017 
Between 2005 and 2017, information on CD4+ T-cell count/mm3 at HIV diagnosis was 
reported on 12,336 (52.6%) cases. Of these, 6,467 individuals (52.4%) had a CD4+ T-cell 
count at diagnosis lower than 350 cells/mm3, including 4,016 cases (32.6%) with a CD4+ 
T-cell count lower than 200 cells/mm3 (Figure 2.3.4). 
 
 
 Source: DGS/INSA 
Note: The category “All cases” includes 11,915 cases for whom place of birth and route of transmission 
was known and an additional 421 cases for whom place of birth was unknown and/or route of transmission 
was unknown or corresponded to other routes of transmission.  
Figure 2.3.4. Proportion of new HIV diagnoses by CD4+ T-cell count/mm3 category at 
diagnosis, by place of birth and main route of transmission, Portugal, 2005-2017 (n = 
12,336). 
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The highest proportions of cases presenting at a later stage of HIV infection (CD4+ T-cell 
count < 350 cells/mm3) were observed in foreign-born (65.6%) and native-born (63.1%) 
men infected heterosexually, while the lowest proportions were observed among foreign-
born (37.8%) and native-born (42.1%) MSM. The proportion of men infected by 
heterosexual route who were late diagnosed is significantly higher than in women, both 
in native (63.1% vs 47.1%, p<0.001) and in foreign-born cases (65.6% vs 47.1%, 
p<0.001) (Figure 2.3.4). There were no significant differences between native and 
foreign-born individuals across the different transmission groups, except in women 
infected heterosexually, where a higher proportion of foreign-born was late diagnosed 
compared to native-born (52,0% vs 47.1%, p < 0.001). 
Between 2005 and 2017, the overall median CD4+ T-cell count/mm3 at diagnosis steadily 
increased from 258 cells/mm3 (IQR: 83–469) to 334 cells/mm3 (IQR: 149–544) (p value 
for trend 0.007). A statistically significant increase was observed in all age groups, except 
the youngest and the oldest individuals, and the incline was the steepest in age group 30-
39 years. Throughout the study period, median CD4+ T-cell count/mm3 at diagnosis 




Figure 2.3.5. Median CD4+ T-cell count/mm3 at diagnosis by age group, Portugal, 2005-






































Total proportion of cases with an AIDS defining illness at HIV diagnosis was 20.9%, 
being higher in native and foreign-born men with heterosexual transmission (29.5% and 
29.6%, respectively) and PWID (28.3% and 26.3%, respectively), without significant 
differences for place of birth (p=0.930 and p=0.480, respectively).  
 
2.3.3.4. Probable place of acquisition of HIV infection, 2005-2017 
Information on probable place of HIV acquisition was reported on 14,798 (63.1%) cases 
newly diagnosed in Portugal between 2005 and 2017. Overall, 83.5% of all cases reported 
Portugal as probable place of HIV acquisition, followed by Portuguese speaking African 




Note: The category “All cases” includes 14,423 cases for whom place of birth, route of transmission and 
probable country of HIV acquisition was known and an additional 375 cases for whom place of birth was 
unknown and/or route of transmission was unknown or corresponded to other routes of transmission.   
Figure 2.3.6. Proportion of new HIV diagnoses by probable country of acquisition of 
HIV infection, by place of birth and main route of transmission, Portugal, 2005-2017 (n 
= 14,798). 
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Portugal was the most reported probable place for HIV acquisition in all transmission 
groups. The second most reported place was Portuguese speaking African countries, both 
by native and foreign-born males infected heterosexually (10.0% and 32.8%, 
respectively). Compared to foreign-born men, a higher proportion of foreign-born women 
with heterosexual transmission reported Portuguese speaking African countries as 
probable place of HIV acquisition (40.7% vs 32.8%, p<0.001), including Guinea-Bissau 
(18.9%), Angola (13.0%) and Mozambique (4.5%) (Figure 2.3.6). European countries 
(1.8%) were the second probable place for HIV acquisition in native-born MSM, while 
foreign-born MSM reported Brazil (28.6%), and native and foreign-born PWID reported 
European countries (1.6% and 10.2%, respectively). 
 
2.3.4. Discussion 
Our analysis shows a sharp decline in the number of new HIV infections in Portugal 
between 2005 and 2017, influenced by a significant decrease in both native and foreign-
born PWID and cases with heterosexual transmission, but not in MSM. However, trends 
in new HIV diagnoses, particularly in recent years, must be interpreted carefully, because 
of known reporting delay [8]. Additionally, existing HIV testing services in Portugal 
might also influence trends. In fact, the increasing trend in new HIV diagnoses observed 
in MSM, particularly after 2011, can be partially explained by the opening of  important 
community-based HIV testing services targeting MSM in Lisbon as well as other projects 
focused on HIV screening funded by the national HIV/AIDS Programme [9]. The trend 
observed both in native and foreign-born MSM can, therefore, be an artefact due to 
increased testing in this key population. On the other hand, the number of diagnoses and 
the male-to-female ratio in foreign-born individuals infected heterosexually must take 
into account different gender behaviours towards healthcare seeking and, in women, 
provision of antenatal care, as HIV screening has been part of routine antenatal testing 
since 2004.  
Overall, MSM represent the second most common transmission group in Portugal but, 
similarly to what is observed in other countries, they are diagnosed earlier than other 
groups. As recognised in the literature, this fact might be linked to increased awareness 








Late diagnosis remains a significant problem, particularly in PWID, in native 
heterosexual men and in foreign-born men and women reporting heterosexual 
transmission, with more than half of HIV cases being late diagnosed in those groups. This 
situation is similar to what is observed in other EU/EEA countries [2,10,11], suggesting 
that access to and uptake of HIV testing remains an important challenge in Portugal.  
HIV diagnoses in older adults (≥ 50 years) in Portugal account for an important share of 
the cases, particularly in native-born men infected heterosexually. These findings 
corroborate the ones described at European level for new diagnosis among adults aged 50 
or older and where Portugal was one of the countries with the highest rate of HIV 
diagnosis for that age group [12].  
Despite a steady decline in recent years, foreign-born persons still account for an 
important proportion (29.7%) of new HIV cases in Portugal. Most of these cases (31.7%) 
indicate Portugal as the country where HIV infection was acquired, particularly PWID 
and MSM, highlighting the need for effective interventions targeting this vulnerable 
population [13-15]. It should also be noted that Portuguese speaking African countries 
were the probable place of HIV acquisition for 10.0% of native heterosexual men, which 
is due to the constant migratory flow to the former Portuguese colonies, particularly 
during the recent economic recession in Portugal [16]. 
Several national policies aimed to address some of these issues are already in place. 
Besides effective harm reduction policies in place since the 1990s [17], guidelines on HIV 
testing and diagnosis have been issued by the Directorate-General of Health  [18]. Since 
April 2018, pre-exposure prophylaxis is available for free in selected Portuguese public 
hospitals, following guidelines from the Directorate-General of Health  [19]. It will be 
crucial to analyse, in the near future, the impact of pre-exposure prophylaxis on new HIV 
infections among MSM in Portugal. Also, legal barriers to HIV self-testing 
commercialisation have been lifted in 2018 [20], making it possible to the provision of 
out-of-counter HIV self-testing kits in all community pharmacies in Portugal since 
October 2019. 
Limitations to our analysis include incomplete data for some variables, including CD4+ 
T-cell count at diagnosis, place of birth and transmission route. This problem has 







improved since 2014, when electronic notification of transmissible diseases became 
mandatory in Portugal. It should also be noted that a small number of cases classified as 
foreign-born correspond to people born in the Portuguese African colonies and moved to 
Portugal after decolonisation in the 1970s. The content of the variable “Probable country 
of acquisition of HIV” infection” might also reflect more the notifying clinician or the 
patient assumption rather than the exact place of transmission.   
Portugal has been successful in sharply reducing its HIV epidemics during the last two 
decades. However, in order to accelerate the decline of new HIV cases, the country needs 
to scale-up efforts to expand effective prevention measures, early diagnosis and continued 
access and retainment in care. Reaching those most-at-risk will require innovative 
approaches and sound national policies. Some important steps were already taken, 
although it is yet too soon to evaluate their impact on the epidemics.  
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2.4. HIV prevention and treatment in Southern Europe in the 
aftermath of bailout programmes 
 
2.4.1. Introduction 
The financial crisis that spread from the USA in 2008 and engulfed Europe had dramatic 
consequences for many European countries [1]. In the context of the Eurozone, the global 
financial crisis became a sovereign debt crisis with several member states struggling to 
repay or refinance their government debts. Several Eurozone countries were particularly 
affected by the crisis. In the context of the Eurozone, Greece, Ireland, Portugal, Spain and 
Cyprus received European Union (EU) financial assistance, with Greece receiving three 
bailout programmes between 2010 and 2018, while programmes in Portugal and Cyprus 
lasted for three years (2011-14 and 2013-16, respectively) and the Spanish programme 
lasted for 18 months (2012-14) [2]. The bailouts included a series of severe austerity 
measures to be implemented by governments over the length of the assistance 
programme.  
Together with a strong economic recession, countries implemented cuts in the health 
sector, including a 30% reduction in Greek health budget in 2012 [1], a 14% reduction in 
health and social services budget in Spain in 2012 [3], and an overall decrease of the 
Portuguese National Health Service budget by 14% between 2010 and 2012 [4]. Other 
cost-containment measures were implemented during the financial assistance 
programmes, namely restrictions to universal health coverage in Spain, since the 
entitlement to health care became based on contributions to the system, excluding young 
people over 26 who have never entered the job market and illegal immigrants from 
receiving health care [5]. In Greece, it is estimated that 2.5 million people (the long-term 
unemployed and their dependents, as well as some other groups) lost their health 
insurance coverage after 2009 and, therefore, access to publicly provided services, during 
the crisis [6]. That situation lasted until 2016, when new legislation to cover people who 
lost insurance coverage was approved.  
The impact of the economic crisis on infectious diseases’ treatment and control has been 








prevention of infectious diseases, including HIV [8,9]. In 2011, a number of HIV 
outbreaks among people who inject drugs (PWID) have been reported in Greece and 
Romania [10,11].  
The current global HIV response aims to mobilise countries worldwide to meet specific 
targets in testing, prevention and treatment. In 2015, the Joint United Nations Programme 
on HIV and AIDS (UNAIDS) called for countries to have 90% of all people living with 
HIV (PLHIV) diagnosed, to have 90% of those diagnosed receiving antiretroviral 
treatment (ART) and to have 90% of those receiving ART virally suppressed, by 2020 
[12]. WHO also issued a series of recommendations in the areas of pre-exposure 
prophylaxis (PrEP), HIV self-testing (HIVST), and treating any person diagnosed with 
HIV irrespective of CD4 count/disease stage [13-15]. 
Our article aims to describe HIV response and progress towards the current global HIV 




We selected four Southern European countries which received economic assistance by 
the EU – Cyprus, Greece, Portugal, and Spain – given the cultural similarity to health 
systems in those countries, three of which also sharing a recent history of democratic 
development. 
We searched for reliable, generalisable, recent country data on WHO, UNAIDS and 
European Centre for Disease Prevention and Control (ECDC) databases and reports as 
well as national reports with the aim of characterising the HIV epidemic, the progress in 
reaching UNAIDS 90-90-90 targets, and the uptake of global norms and standards on 
HIV prevention, testing, and treatment. We communicated with public health officials in 
the HIV programmes within each of these countries to validate and complement our 
findings, recognising that each country has unique features in terms of health system and 
HIV policy prioritisation. 
For our analysis, we considered the following indicators:  







a) HIV epidemiology – total number of new HIV cases per 100,000 population 
reported to ECDC between 2005 and 2017; 
b) adoption of Treat All – status of each selected country regarding the adoption of 
WHO’s recommendation that all people diagnosed with HIV should immediately 
initiate ART irrespective of disease stage/CD4 count, describing the number of 
PLHIV receiving ART in 2008 and in the most recent year available; 
c) progress towards the UNAIDS global targets of 90-90-90 – for 2013-14 and the 
most recent year available, we included official country data on the percentage of 
PLHIV who knew their status, percentage of diagnosed PLHIV who were 
receiving ART and percentage of PLHIV receiving ART who were virally 
suppressed; 
d) adoption/implementation of PrEP – status of each selected country regarding the 
formal implementation of PrEP as of November 2019, in the context of the 
EU/European Economic Area (EEA); and 
e) adoption/implementation of WHO’s HIV self-testing (HIVST) recommendation – 
status of each selected country regarding the formal implementation of HIVST as 
of July 2019, in the context of the EU/EEA. 
We complemented the characterisation of  national policies regarding PrEP and HIVST 




2.4.3.1. HIV epidemiology 
While men who have sex with men (MSM) is the main route of HIV transmission in 
Cyprus, Greece and Spain, heterosexual contact is the main HIV transmission mode in 
Portugal [16]. The selected countries show different trends in HIV incidence rates during 
the analysed period (Figure 2.4.1). Portugal recorded in 2005 19.6 new HIV cases per 
100,000 population, a figure four times higher than in Cyprus and three times higher than 
in Greece. There was a steady decrease on HIV incidence rate in both Spain and Portugal 








assistance programmes. By 2017, Portugal’s HIV incidence rate (10.3) had converged 
with Cyprus (10.0), still being almost two times higher than in Greece (5.8) (Figure 
2.4.1). Greece reported an increase in new HIV infections between 2010 and 2012, 
reaching a peak of 10.3 cases per 100,000 population in 2012  (Figure 2.4.1). During this 
period the country has experienced an outbreak of HIV among injecting drug users, with 
the number of newly diagnosed cases increasing from 29 in 2010 to 523 in 2012 in this 
group. HIV incidence decreased in the following years but the number of new cases 
among injecting drug users in 2017 (n=86) remains over seven times higher than in 2007 
(n=12). In Cyprus, HIV incidence rate has increased since the onset of the economic crisis 
in 2010, and particularly during the economic adjustment programme (2013-16). The 
number of new HIV cases in the country by the end of 2017 (n=85) was twice as much 
as in 2010 (n=41) [16]. 
 
 
Source: ECDC [16] 
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2.4.3.2. Treat all 
In 2013, WHO recommended that ART should be initiated in all individuals with HIV 
with CD4 count between 350 and 500 cells/mm3 regardless of WHO clinical stage [17]. 
Later, in 2016, WHO updated and launched new policy recommendations on the clinical 
and service delivery aspects of HIV treatment and care, and raised the bar to treat all 
PLHIV irrespective of CD4 count [13]. The main purpose of this policy was to link and 
retain all people infected by HIV in appropriate care without waiting for deterioration of 
their immunological status, as it became evident that early initiation of ART is beneficial 
both to the health of the person being treated and in preventing onward HIV transmission 
[18,19]. 
In 2014, Spain used the threshold of CD4 count below 500 cells/mm3 to initiate ART, 
while Cyprus, Greece and Portugal were generally still using the CD4 count below 350 
cells/mm3 [20]. As of 2016, all selected countries have adopted WHO’s recommendation 
of initiating ART regardless of CD4 count [20]. As a consequence, the number of PLHIV 
receiving ART has shown a remarkable increase over the recent years in all selected 
countries. Although there is no data available for 2016, Cyprus has increased the number 
of PLHIV receiving ART by 47% (from 170 in 2008 to 250 in 2014) [21,22]. In Greece, 
the number of PLHIV receiving ART more than doubled between 2008 and 2017 (from 
4,236 to 9,594) [21,23], the same happening in Portugal (from 12,366 in 2008 to 31,000 
in 2016) [21,23]. Finally, in Spain the number of PLHIV receiving ART increased by 
41% between 2008 and 2016 (from 82,710 to 116,408) [21,23]. 
 
2.4.3.3. Meeting the 90-90-90 targets 
In 2014, the UNAIDS launched the 90–90–90 targets, the aim of which was to scale-up 
global HIV response as part of an overall strategy to end AIDS epidemic by 2030. By 
2020, countries should aim to have 90% of all people living with HIV diagnosed, to have 
90% of those diagnosed receiving sustained ART, and to have 90% of those receiving 
ART with viral suppression [12]. These ambitious targets have been regularly monitored 
globally, and countries have reported significant progress towards reaching the 90-90-90 











































Sources: 2013-14 data – ECDC [23]; 2016 data – National Centre for Epidemiology/National AIDS Plan [26]  
Note: No data available for Cyprus. 
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In Greece, as of 2016, approximately 20% of people living with HIV do not knew their 
status. The proportion of people who have begun ART increased from 68% in 2013 to 
88% in 2016, as a result of Greek guidelines introducing the Treat All recommendation 
in 2015. One of the challenges in Greece is that, as of 2016, there is an absence of viral 
load testing within the national HIV treatment programme. Nonetheless, as of 2016, 82% 
of PLHIV were virally suppressed, based on the Greek cascade-of-care analysis. 
By the end of 2017, Portugal has reached all 90-90-90 targets (Figure 2.4.2.). As in Greece, 
Portugal adopted new guidelines on HIV treatment, introducing the Treat All 
recommendation in 2015 [24]. The country has been successful in diagnosing HIV 
infections – with an estimated 8% of PLHIV who do not know their status as of 2017 – 
and expanding ART – with an estimated 10% of diagnosed PLHIV who were not 
receiving ART by the end of 2017 (Figure 2.4.2.). In 2016, Portugal recorded 91.7% of 
PLHIV diagnosed, 86.8% of those diagnosed receiving ART, and 90.3% of those 
receiving ART virally supressed [25]. 
As of 2016, Spain was very close to reach UNAIDS targets for HIV treatment, but 
additional efforts are needed to increase the proportion of PLHIV who know their status: 
as of 2016, around 14% of PLVIH do not knew their status [26]. 
 
2.4.3.4. Implementing pre-exposure prophylaxis 
As of September 2015, WHO recommends that people at substantial risk of HIV infection 
(e.g. men who have sex with men who do not consistently use condoms) should be offered 
PrEP as an additional prevention choice, as part of comprehensive prevention [13]. 
Several countries have implemented either pilot (demonstration projects) or full-scale 
PrEP programmes [27]. 
Portugal has joined other Western and Northern European countries where the 
government has been offering PrEP under the public sector (Figure 2.4.3). Among the 
selected countries, Portugal was the first to publish a national guidelines document, and 
thus, to implement a policy on PrEP [28]. PrEP is currently being provided for free at 
hospital setting only, upon referral for PrEP consultation. PrEP delivery has been in place 









In 2019, a technical working group convened by the Greek Ministry of Health submitted 
an implementation plan for PrEP. This plan is a key pillar of a broader national HIV 
strategic plan proposal that was submitted at the same time to the Ministry. Currently, 
there is no formal access to PrEP in the public or private health system in Greece. A PrEP 
demonstration project was completed in May of 2019, and project participants were not 
offered sustained access to PrEP upon completion. The Greek national plan proposes 
PrEP being provided for free under the national health system, while it also recommends 
that PrEP is available in pharmacies with a prescription for an out-of-pocket payment. 
The process of PrEP implementation in Spain has started in September 2016 [29], and 
since 2017 two pilot projects are in place in the country: one in Barcelona and another 
one in San Sebastian/Donostia [30]. In October 2019, the Spanish Inter-ministerial Price 
Commission agreed on the inclusion of PrEP in the health services package and PrEP 
started to be provided in the public sector by the end of 2019 [31]. 
 
 
Source: Authors based on ECDC data 
Figure 2.4.3. Status of formal PrEP implementation, EU/EEA, November 2019. 







Lastly, for Cyprus, PrEP as a policy is not in place. A community-led consultation in 
partnership with the Ministry of Health took place in May 2019. There are ongoing plans 
to further engage Ministry of Health, WHO, and civil society on how to effectively 
introduce PrEP. Most recently, a PrEP technical working group will be convened in the 
first quarter of 2020 to ensure access is expedited for people living in Cyprus 
 
2.4.3.5. Implementing HIVST  
HIVST has not been adopted in Cyprus or Greece (Figure 2.4.4). In Greece, a current 
ministerial decree makes it illegal for any HIV test to be imported, marketed and sold as 
an HIV self-test [32]. Any effort to introduce HIVST in the country, even in the setting 
of an implementation research study, would require a new ministerial decree to be issued. 
That was the case in Spain and Portugal. In Spain, a Royal Decree of 2017 regulated the 
commercialisation of health devices for in vitro diagnosis, making it possible selling HIVST 
 
 
Source: Authors based on WHO data 








in community pharmacies [33]. Since January 2018, HIVST kits are sold in pharmacies 
in Spain without medical prescription at a cost of approximately 29 EUR [34]. Likewise, 
in October 2018, the Portuguese government lifted existing legal barriers to allow the 
commercialisation of HIVST in community pharmacies [35], but it was not until October 
2019 when HIVST kits became available at community pharmacies in Portugal without 
medical prescription, at a cost of approximately 25 EUR [36]. 
 
2.4.4. Discussion 
Our findings show that all selected countries successfully implemented WHO’s Treat All 
recommendation, with a remarkable increase of the number of PLHIV receiving ART. 
As of 2017, Portugal has already met all UNAIDS 90-90-90 targets for HIV treatment, 
while, as of 2016, Spain was very close to meet those targets, needing to strengthen efforts 
to increase the percentage of PLHIV who know their status. As of 2016, Greece was still 
falling behind all three targets. Among all four selected countries, Portugal is the only 
one with both PrEP and HIVST nationally implemented, while Cyprus was the only one 
with no implementation of either of these policies. Spain has had an HIVST policy in 
place, and has most recently mad PrEP available through its national health system, with 
Catalonia and Madrid regions already providing PrEP, as of January 2020. Greece 
completed a PrEP pilot in May 2019, and a formal implementation plan has been 
submitted to the Ministry of Health as of July 2019. A transition to a new government in 
July 2019 has resulted in a delay to PrEP access in Greece, and all pilot participants were 
not offered to continue on PrEP after pilot completion, which raises ethical concerns. 
HIV incidence trends observed in the four countries vary. Despite a severe economic 
downturn coupled with austerity measures, where one could have expected an increase in 
HIV transmission, HIV incidence has been decreasing since 2008 in both Portugal and 
Spain. In contrast, HIV incidence has increased in Greece, mainly due to an HIV outbreak 
among PWID, with the number of new HIV infections in this population increasing 15-
fold from 2010 to 2011. This outbreak has been well characterized in the literature 
[37,38], and response in Greece was to invest in resources to ‘seek, test and treat’ people 
within those injecting/sexual networks of PWIDs. A programme entitled Aristotle 







Programme was activated to promote testing and strengthen linkage to harm reduction 
services for PWIDs in Athens, resulting in a reduction in new HIV cases in 2013 [39]. In 
Cyprus, HIV incidence has increased following the implementation of the assistance 
programme. The country has witnessed an increasing number of new HIV cases among 
MSM, exposing the lack of an effective HIV response targeting this key population. 
Stigma against PLHIV, poor sexual health information activities, and lack of anonymity 
and confidentiality in HIV testing services provided by the public sector were pointed as 
red flags in the Cypriot HIV response [22].    
A number of reasons in each of the four selected countries may have played a role in 
explaining the differences observed in HIV policies. Although anticipated general 
elections took place in Portugal in June 2011, following the bailout, both Spain and 
Portugal had political stability during the implementation of the respective adjustment 
programmes. In contrast, Greece experienced frequent political change between 2010 and 
2015; also, in Cyprus, the bailout programme determined a change in government in 
2013. Thus, implementation of HIV policies has had different prioritization among the 
selected countries, with policies taking longer time to be implemented where political 
environment was not favourable. Also, the different economic context in each country 
could have played a role in funding HIV programmes or, at least, in making that funding 
a priority. Finally, a generally weak primary care and prevention services in Greece and 
Cyprus, as well as worse access and financial protection, might have also influenced 
different results in those countries. With one the highest HIV incidence rates, tackling 
HIV remained a political priority in Portugal and policy implementation continued 
despite the economic crisis. The resilience of the Portuguese health system and the strong 
civil society might also explain the results achieved in the country. Additionally, the 
country has had a progressive drug policy implemented for about two decades, in contrast 
with countries like Greece and Cyprus, which might also have reflected on the countries’ 
response to HIV. 
As HIV transmission remains a major public health challenge for EU/EEA countries, the 
adoption of multicomponent interventions and the inclusion of PrEP and HIVST into the 
package of prevention and control interventions could help current interventions [16]. 








of care. In our analysis, Portugal stands as a successful example among the selected 
countries: despite a very difficult period of financial assistance and economic downturn, 
the country kept its HIV incidence declining while expanding testing and treatment. A 
number of reasons may explain this situation. Besides transitory cuts in its budget in 
2012-13, the Portuguese HIV/AIDS Programme prioritised investments in expansion of 
HIV prevention and testing through community-based organisations. In fact, these 
organisations played an essential role in effectively reaching those at-risk groups with 
condoms and HIV rapid testing. Portugal has successfully increased the number of 
PLHIV receiving ART, suggesting that the Portuguese National Health Service was able 
to respond well to the additional number of people who needed ART dispensing. A strong 
political prioritisation of HIV/AIDS enabled the expansion of HIV testing and treatment 
and the effective monitoring of the HIV continuum of care, thus allowing Portugal to 
meet the UNAIDS 90-90-90 targets by the end of 2017. In contrast, failures in HIV 
response due to budgetary cuts and/or lack of prioritisation could have made progress in 
other countries, like Greece or Cyprus, less significant.  
There is growing evidence suggesting that PrEP is highly effective in accelerating the 
reduction of new HIV infections in health jurisdictions where appreciable levels of 
coverage in people at risk for HIV is achieved. This has been reported and well 
characterised for settings that include New South Wales (Australia), London (UK) and 
San Francisco (USA) [40-42].  
Countries implementing PrEP, including Portugal, which has made PrEP available 
through a hospital-based roll-out, should consider mechanisms to facilitate access to PrEP 
and can maximize impact by scaling up coverage: e.g. make PrEP available at community 
pharmacies under medical prescription or having it delivered by community-based 
organisations. 
Limitations to our study include the unavailability of HIV cascade data from Cyprus, 
which did not allow a wider comparison and analysis, and the lack of more recent data 
for the remaining countries in this analysis. Lastly, it must be recognised that the 
understanding of each country’s policy process and health prioritisation is a very complex 
and difficult task that must consider several factors left aside of this analysis. 







The global financial crisis impacted public health in Europe, and had a particularly critical 
detriment to health systems in Southern Europe. In the context of HIV, the austerity 
measures, which were implemented in some countries in Southern Europe had 
implications for both HIV prevention and treatment.  
The set of HIV indicators in our analysis addressed public health outcomes alongside 
policy adoption of new interventions recommended by WHO. Our key finding was that 
from the four countries compared, Greece, which experienced the longest assistance 
programme, had its health system weakened, which in turn resulted in adverse outcomes 
(defined by new HIV infections). In contrast, Portugal stands out as a country that 
successfully expanded HIV prevention and treatment and was able to meet the UNAIDS 
90-90-90 targets and implement PrEP and HIVST nationally. Results from our analysis 
stress the importance of analysing national HIV policies and country progress in order to 
strengthen HIV response.   
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3. GENERAL DISCUSSION AND CONCLUSIONS 
 
3.1.  General Discussion 
The current global HIV response aims to mobilise countries worldwide to meet specific 
targets in testing, prevention and treatment. By 2020, UNAIDS calls for countries to have 
90% of all people living with HIV (PLHIV) diagnosed, to have 90% of those diagnosed 
receiving antiretroviral treatment (ART) and to have 90% of those receiving ART virally 
suppressed [1]. Simultaneously, countries must adopt innovative strategies to tackle HIV 
infection, including pre-exposure prophylaxis (PrEP). Those efforts demand sound 
national policies, that are able to reach those most-at-risk, as well as adequate and 
sustained funding, in order to meet the goal set for 2030: end AIDS. This unprecedented 
global commitment to meet these targets was launched in the aftermath of a severe global 
financial crisis, that forced many countries to reduce health care spending. 
The global financial crisis hit particularly Eurozone countries, which were in a limited 
position of facing such macroeconomic and financial shocks. Additionally, some 
countries accumulated imbalances and fragilities (eg low growth rates, high government 
deficit, high public debt) that made them exceptionally vulnerable when the turmoil of 
the crisis engulfed Europe [2]. The EU’s response to countries struggling to finance their 
economies in financial markets was the creation of mechanisms of financial assistance. 
Five Eurozone countries (Greece, Ireland, Portugal, Spain and Cyprus) received bailouts 
from the European Union, European Central Bank and International Monetary Fund. 
Those financial rescue programmes were coupled with severe austerity measures that 
were aimed at containing costs and increase revenue in order to readjust countries’ 
imbalances. The effect of those austerity measures on population health and on countries’ 
health systems has been subject of research but also intense debate [3,4].    
This study aimed to analyse the potential effects of those financial constraints on HIV 
response and national policies in Portugal, placing the country in the context of other 
Southern European countries that received bailout programmes. This section provides a 
comprehensive discussion of the findings from each study.   







3.1.1. Provision of hospital care to PLHIV 
The analysis of HIV/AIDS patients length of stay (LOS) between 2009 and 2014 found 
a significant decrease in LOS. A number of variables, including urgent admission, in-
hospital mortality, pneumocystis pneumonia, hepatitis C, and the hospital's current ratio 
contributed to the decrease of LOS in HIV/AIDS patients in Portuguese hospitals [5]. The 
inclusion of a dummy variable to capture the implementation of the financial assistance 
programme and its effect on LOS allowed no definitive conclusion. In fact, the year 
dummies remained statistically significant, even after introducing the variable measuring 
hospitals’ current status. The fact that the annual decrease in LOS for HIV/AIDS patients 
was not explained by the hospitals’ current status, suggests a generalized pressure to 
reduce costs not fully related with the hospitals’ financial situation. In fact, as public 
hospitals were facing a severe financial situation, a number of cost-containment measures 
aimed at increasing efficiency in the health sector were implemented in the scope of the 
financial assistance. The Memorandum of Understanding (MoU) established the 
reduction of hospitals’ operating costs as a priority [6,7], which is the reason why 
hospitals belonging to the Portuguese National Health Service (NHS) were under 
continuous pressure to cut costs during the period of the adjustment programme. Our 
findings suggest that this was an important factor contributing for the decrease of LOS 
among HIV/AIDS patients, but there were other factors playing a role.  
PLHIV were not affected by the increase of user charges in the NHS that took place in 
2012, following the financial assistance programme [8]. This increase was coupled with 
a review of exemption rules, and PLHIV, as chronic patients in need of frequent 
healthcare, were excluded of paying user charges for their follow-up at the NHS [9]. The 
provision of antiretroviral treatment (ART) to all PLHIV continued to be free, even if 
anecdotal evidence suggests that some hospital were running out of ART or were 
rationing drugs [10,11]. Currently, delays in ART dispensing in Portugal seem to be still 
a reality [12,13].    
Although our findings do not allow to draw any conclusion on the decreasing of quality 
of health care provided to HIV/AIDS patients in Portuguese hospitals, evidence from 
Greece and Spain suggests a deterioration in the quality of publicly provided health care 
[14,15].  







Despite the intense debate on the austerity measures implemented in the health sector in 
Portugal, most of them did not affect access to services, but instead targeted the system’s 
costs [7]. Due to chronical management problems and persistent inefficiencies, several 
measures in the MoU aimed to increase savings and make the Portuguese NHS more 
efficient [7,16]. Cuts in salaries of public servants, including all NHS personnel, also 
helped to contain costs during the adjustment programme. The decreasing LOS in 
HIV/AIDS patients found in our analysis illustrates the pressure on public hospitals to cut 
costs during the period of the bailout. However, overall, austerity measures did not affect 
HIV/AIDS patients’ access to public provided health care, although some problems with 
ART dispensing were (and still are) reported. 
 
3.1.2. HIV response 
The reform operated in the Portuguese HIV/AIDS Programme in 2012 coincided with the 
implementation of the MoU in the scope of the financial assistance programme to 
Portugal. The body responsible for coordinating HIV response in Portugal was created in 
the mid-1980s and its relevance increased as the epidemics spread in the country, during 
the 1990s. The main purpose of this reform was to reorganise a set of public health 
programmes, while reducing costs and increase their efficiency. Findings from this study 
show a transitory period of budgetary cuts in the National Programme for HIV/AIDS 
Infection, that coincided with the peak of the crisis (2012-13).  
Firstly, the amounts available for funding non-for-profit organisations were cut: very far 
from the EUR 9.4 million available in 2008, currently the amounts available for funding 
community projects are approximately EUR 3 million. Spending in the syringe exchange 
programme, HIV rapid testing and preventive materials (male and female condoms, and 
lubricant) was also cut until 2013. From 2014 onwards, spending in all those core 
prevention programmes started to increase.  
However, the most important finding from this analysis is the pivotal role played by non-
governmental organisations/community-based organisations (NGOs/CBOs) in the 
country’s HIV response. In fact, findings from this study show a smart move from the 
HIV/AIDS Programme by specifically including the provision of HIV testing (as well as 
other sexually transmitted infections) in the terms of reference of projects funded by the 







Programme. Hence, HIV testing was remarkably expanded from 2013 onwards, as those 
organisations provide proximity services, particularly near key populations. This was a 
decisive step to meet the first 90 of the UNAIDS targets: have 90% of all PLHIV 
diagnosed [1].  
Fundamentally, the current global health agenda for HIV/AIDS is focused in closing three 
major gaps. The first one is the prevention gap: innovative tools such as PrEP should be 
part of multicomponent interventions to prevent new HIV infections. The second gap is 
the diagnosis gap: again, interventions to expand HIV diagnosis should include wide 
availability of rapid diagnostic services, community-based HIV testing as well as 
innovative approaches such as HIV self-testing and assisted voluntary partner 
notification. Finally, the third gap is the treatment gap: rapid linkage and retainment in 
quality HIV treatment and care is crucial to ensure that PLHIV are receiving ART and 
are virally suppressed, therefore not transmitting HIV. Closing those three gaps is a 
challenging and dynamic process that demands enabling policies, appropriate funding 
and regular monitoring.  
A number of policies help to explain the path of Portugal in reducing its HIV epidemics. 
In fact, in 1993 the country started the Syringe Exchange Programme in partnership with 
community pharmacies, wholesales and municipalities [17]. This harm-reduction 
programme aimed at reducing new HIV infections among people who inject drugs 
(PWID), as HIV infections were mainly associated to injecting drug use. Additionally, 
the country enacted a progressive drug policy, including the decriminalisation of all 
personal drug use in 2001, moving the focus from criminal justice to a public health 
approach [18]. When pharmacies cancelled the agreement with the HIV/AIDS 
Programme in the end of 2012, this important programme was immediately transferred 
to Public Health Units at primary health care, so that the service of needle exchange would 
not be interrupted. Community-based organisations also operated the distribution of 
syringe kits, including night schedules, in the areas where they were most needed. As a 
result, there was no increase in the number of new HIV diagnosis among PWID during 
these years.  
The engagement with civil society organisations is a key element of the Portuguese 
HIV/AIDS Programme that is pivotal to explain the success of HIV policies in the 







country. During the peak of the economic crisis, which coincided with the reform of the 
HIV/AIDS Programme, civil society organisations assured the distribution of preventive 
materials, provision of HIV testing services and kept their community-based projects 
running, despite facing financial constraints.  
 
3.1.3. HIV epidemics 
The analysis of national surveillance data on HIV cases in Portugal between 2005 and 
2017 showed a significant decrease in the number of HIV diagnoses attributed to 
heterosexual transmission and injecting drug use both in native and foreign-born people. 
In contrast, the number of HIV cases in both native and foreign-born men who have sex 
with men (MSM) showed a non-significant increasing trend. This finding need to be 
interpreted in the scope of the expansion of HIV testing targeting MSM that occurred 
after 2011. Only further research will allow to conclude if  this finding shows an increased 
HIV transmission among MSM or is an artefact due to HIV testing services.   
However, MSM are diagnosed earlier than any other group. In contrast, high proportions 
of people infected heterosexually, particularly native-born men, are diagnosed in older 
age. Late HIV diagnosis is still common in Portugal, with more than half of the cases 
where a CD4+ T-cell count/mm3 at HIV diagnosis was reported, being diagnosed below 
350 cells/mm3. This proportion is particularly high among native and foreign-born men 
infected by heterosexual route. In fact, median CD4+ T-cell count/mm3 was the highest 
among younger cases and the lowest among older cases.  
Heterosexual sex remains the predominant mode of HIV transmission in Portugal and 
prevention strategies need to focus on older age heterosexuals in order to keep effectively 
reducing new HIV diagnosis in the country. The recent implementation of HIV self-
testing in Portugal as well as the provision of HIV rapid testing in community pharmacies 
are expected to make HIV testing more available for this group [19,20].  
The proportion of foreign-born individuals who have acquired HIV infection outside 
Portugal is still relevant, as it is the proportion of native-born men infected heterosexually 
who have acquired HIV abroad. The close ties between Portugal and its former colonies 
is evident, with Portuguese African speaking countries being the most probable place of 







HIV infection for foreign-born men and women; Brazil stands as the most probable 
country of HIV infection for foreign-born MSM.  
The trends observed in this analysis confirm two important achievements of HIV policies 
in Portugal. The first one is the success of prevention interventions is significantly 
declining new HIV diagnoses in the past twenty years. The second one is the remarkable 
expansion of HIV testing, that is crucial to confirm the reduction of new HIV cases in the 
country. Years ago, HIV rapid testing was mainly concentrated in HIV testing and 
counselling centres, but it became increasingly available, through public funds, at 
community-based organisations, primary health care units, pharmacies and laboratories. 
Simultaneously, HIV testing was made mandatory for antenatal care, which was crucial 
for early diagnosing many HIV cases and eliminating of mother-to-child transmission in 
Portugal [21]. Finally, doctors were encouraged to prescribe HIV tests to their patients 
and appropriate guidance was issued for that purpose [22]. Although the number of  HIV 
tests requested at public primary health care centre decreased between 2010 and 2013, 
probably due to pressure to reduce costs during the crisis, it shows an increasing trend 
between 2013 and 2017, with Portugal recording a rate of 24.3 HIV tests per 1,000 
population in 2017 (excluding HIV tests requested in hospitals, private sector, testing of 
blood donors and unlinked anonymous testing) [23]. 
 
3.1.4. HIV policies in context 
When comparing Portugal to other Southern European countries that received economic 
assistance programmes, findings put the country in an outstanding position. The declining 
trends in new HIV diagnoses observed in Portugal and Spain contrast with increasing new 
HIV cases in Greece and Cyprus. While in Greece there was an HIV outbreak among 
PWID, which was linked to cuts in prevention programmes, in Cyprus the increase in 
new HIV diagnoses among MSM exposes the lack of an effective HIV response targeting 
key populations. Despite halving the number of new HIV diagnoses in just one decade, 
Portugal still recorded the highest HIV incidence rate among the four countries, as of 
2017. 







All countries have adopted the WHO recommendation of initiating ART to all people 
diagnosed with HIV irrespective of their CD4 count, but the pace of increasing the 
number of PLHIV receiving ART was different across the analysed countries. In fact, by 
2016, Greece had not yet met any of the UNAIDS 90-90-90 targets, while in the same 
year both Spain and Portugal had achieved two of the three targets set by UNAIDS. In 
2016, Spain was missing the first 90 (to have 90% of PLHIV knowing their status) and 
Portugal was missing the second 90 (to have 90% of diagnosed PLHIV receiving ART). 
By the end of 2017, Portugal met all the UNAIDS targets for HIV treatment, three years 
ahead of the 2020 deadline.  
Findings from this study also show that, among the four selected countries, Portugal was 
the only one who had implemented both PrEP and HIVST nationally. By 2019, Spain had 
also implemented HIVST but the country had not yet been successful in implementing 
PrEP nationally. Greece is still developing its HIVST policy and PrEP is part of the 
country’s strategic plan for HIV/AIDS. Finally, Cyprus was the only one, among the four 
selected countries, with no policy on PrEP or HIVST.  
The reason why Portugal stands out among the Southern European countries that received 
assistance programmes during the financial crisis (and even in the context of the EU) lays 
on several reasons. Firstly, the country has shown a strong commitment to mounting a 
strong HIV response since the emergence of the epidemic in the 1980s. The prioritisation 
of HIV in health policies in Portugal has been consistent across all political and economic 
cycles. Secondly, the Portuguese National Health Service was a pivotal element in the 
country’s HIV response. Portugal has always provided free HIV treatment and care, to 
all people eligible to start ART, including undocumented migrants. The eligibility to start 
ART changed across the years, until the adoption, in 2015, of the WHO recommendation 
of initiating ART to all people diagnosed with HIV, irrespective of their clinical 
stage/CD4 count. Thirdly, the Portuguese HIV/AIDS Programme has been a crucial 
stakeholder in coordinating the country’s HIV response, by involving reputed national 
experts and engaging with civil society. The implementation of a evidence-based and 
people-centred HIV response made it possible to achieve important reductions in the HIV 
epidemic in a very short time. Fourthly, the development of a strong HIV response among 
civil society organisations was crucial to expand HIV prevention and diagnosis and reach 







those most-at-risk effectively. Lastly, Portugal has operated important improvements in 
its HIV surveillance. HIV/AIDS became a mandatory notifiable disease, an electronic 
notification system was implemented, and a constant monitoring of reported cases is 
carried out jointly by the HIV/AIDS Programme and the National Institute of Health. 
 
3.1.5. Limitations 
This study has a number of limitations. To analyse the potential effects of austerity 
measures adopted in the scope of a financial crisis on a country’s HIV policy is difficult, 
complex and potentially biased [24]. In fact, the lack of measures to monitor the impact 
of crisis on health systems and on population health makes it difficult to measure the 
effects of austerity policies implemented. It would be misleading and methodologically 
wrong to establish causality between austerity measures and specific health or policy 
outcomes, although a number of studies have made those associations [25-30]. The 
understanding of a country’s policy process and health prioritisation is a very complex 
and difficult task that must consider several factors left aside of this study. 
Another methodological limitation of this study was the use of national secondary data to 
conduct analysis. This research would have benefited of a qualitative approach that could 
have add insight of important stakeholders on the findings of this study.  
Important elements of HIV policy were left aside of this research. One of them is the price 
of ART in Portugal and how generics have lowered that price. The important 
pharmaceutical reform carried out during the assistance programme has encouraged the 
introduction of generic drugs both on ambulatory and on hospital care as a way to produce 
savings to the health system. In fact, in 2018 Portugal saved around EUR 15.8 million (-
7.4%) on antiretroviral drugs for HIV, comparing to 2017 [31]. However, the total amount 
spent in 2018 (EUR 199 million) falls well behind the EUR 230 million the country spent 
on ART in 2012 [32].  
Also, the analysis of HIV/AIDS patients’ length of stay did not allow to draw conclusion 
on the increase or decrease of the health care provided in Portuguese hospitals during the 
implementation of the economic assistance programme.  







Finally, the lack of comprehensive data from other countries that received financial 
assistance and the imperfect knowledge on the effects of austerity measures on their 
health systems and national HIV policies prevented a more informed comparative 
analysis between Portugal and other bailed out Southern European countries.   
 
3.1.6. Policy implications 
This study aimed to analyse the role played by the austerity measures implemented in the 
context of the economic and financial assistance programme in Portugal on the country’s 
HIV response and national HIV policies. Findings from this research are expected to 
contribute to the literature on this issue but also to draw policy implications that can guide 
decision makers in future economic downturns. Results from this study are therefore an 
important contribution to the knowledge and understanding of Portugal’s HIV policy under 
financial constraints and are useful to characterise the country’s progress towards AIDS 
elimination.  
A number of policy implications can be outlined from the results of this study. Findings from 
this research suggest that the implementation of austerity measures in Portugal may have 
influenced transitory cuts in the budget of the national HIV/AIDS Programme. The 
prioritisation of available resources and the strong engagement with civil society 
organisations were pivotal to maintain a sustained an effective provision of  HIV prevention 
programmes. However, it is important for policy makers to understand when increasing 
efficiency gives place to flaws in HIV response. Spending in HIV prevention must be oriented 
towards the implementation of evidence-based and people-centred approaches, and the role 
of civil society organisations seems to be crucial to the success of the Portuguese HIV 
response. Decision makers should be informed of potential step backs in national HIV 
response if further budgetary adjustments are to be considered.  
The significant decrease of new HIV cases in Portugal observed in recent years is the result 
of several policies implemented, including harm-reductions programmes, expansion of HIV 
prevention and accessible HIV rapid testing. However, results from this study show that 
foreign-born individuals, most of them migrants, account for approximately 30% of new HIV 
cases in Portugal, most of them indicating Portugal as the country where HIV infection was 
acquired. These findings highlight the need for effective interventions targeting this 







vulnerable population, eliminating existing barriers to health care [33]. Also, the relevant 
percentage of cases who are late diagnosed calls for urgent actions to successfully reach older 
age groups, particularly native and foreign-born men infected heterosexually.  
Finally, as Portugal is one of the countries who implemented PrEP and HIVST, it is important 
to expand the utilisation of these innovative approaches in order to accelerate the declining 
of the HIV epidemics in the country. One the one side, HIVST has the potential of reaching 
many individuals who do not use health services and do not primarily seek HIV testing, 
making it more available to them. In addition, PrEP stands a valuable preventive tool that 
should be available to a larger group of the population. With approximately 600 people 
receiving PrEP at the Portuguese National Health Service by the end of 2018 (excluding all 
those that buy PrEP through the internet), the number of people who access PrEP in Portugal 
must be dramatically expanded in order to achieve appreciable levels of coverage and, 
therefore, have impact on the HIV epidemics. Countries implementing PrEP should consider 
mechanisms of access that facilitate individuals to get PrEP as easily as possible and can 
maximize impact by scaling up coverage. One approach is making PrEP available in 
community pharmacies with a prescription with an out-of-pocket expenditure [34,35]. Such 
models of care have been instrumental in facilitating access in Netherlands (estimated 7,000 
people taking PrEP), Poland, Ireland, Italy, Germany and Austria. Another approach entails 
‘de-medicalizing’ PrEP, whereby PrEP can be delivered by community-based organisations. 
These approaches must be considered by decision makers in Portugal. 
Finally, it is important to constantly monitor the implementation of these innovative 
strategies, as it is to strengthen HIV surveillance by taking full advantage of electronic 
systems implemented in the Portuguese NHS. The successful partnership established with 
two national bodies (the National Institute of Health and the Directorate-General of Health) 
for the concretisation of this study is a good example of how academia and national public 
health agencies can cooperate to analyse policies and produce scientific knowledge that can 
be translated to decision making. 
 







3.2.   Conclusions 
This study analysed Portugal’s HIV epidemic and national response in the context of the 
economic assistance programme implemented between 2011 and 2014 after the global 
financial crisis, and how austerity measures implemented in the country have potentially 
impacted in HIV policies and the country’s response to the epidemic.  
Despite some transitory cuts in funding in 2012-13, the HIV/AIDS Programme in Portugal 
was able to maintain its activities and even largely expanding not only HIV prevention 
interventions but HIV testing services. Portugal also shows a significant decrease in new HIV 
cases among native and foreign-born individuals, except in men who have sex with men. 
Additionally, the country has successfully implemented international recommendations on 
HIV treatment and has met the UNAIDS 90-90-90 targets ahead of the 2020 deadline. 
Portugal was also able to implement innovative approaches such as pre-exposure prophylaxis 
and HIV self-testing nationally. The results from this study show that financial constraints 
experienced in Portugal until recently have not hampered the country’s progress in fulfilling 
its political commitments with ending the AIDS epidemic by 2030.  
Our study has identified a number of reasons that explain our findings and make Portugal an 
interesting case study in the European context. The strong prioritisation of HIV/AIDS in the 
country’s health policy, the response from the universal National Health Service, the 
engagement with civil society organisations and the adoption of evidence-based and people-
centred policies are pivotal elements to explain why HIV response did not collapse when hard 
financial constraints were imposed to the country.  
This study aimed to make an important contribution to the understanding of the potential 
impact of austerity measures on health policies and public health. Firstly, because the subject 
is original in the Portuguese and European literature on this issue; and secondly, because 
findings from this study can stand as a useful guidance to decision makers in future economic 
downturns. 
Policy implications that can be outlined from the results of this study include the need of 
maintaining adequate funding for HIV prevention programmes, namely through the 
engagement with civil society organisations; the importance of implementing effective 
interventions relevant to migrant populations as well as older age population groups who are 
still late diagnosed; and the opportunity to consider the expansion of the delivery of PrEP to 







other settings, namely community pharmacies and community-based organisations, in order 
to take full advantage of the potential effects of this innovative tool on the HIV epidemic.  
In conclusion, the implementation of the economic assistance programme had severe social 
and economic consequences to Portugal. However, the country’s HIV response and national 
policies were preserved, with no detrimental consequences on the epidemic nor service 
provision. Portugal stands out as an example of strong engagement in tackling HIV epidemic 
and must take the opportunity to further reduce new HIV cases by taking full advantage of 
available innovative approaches implemented in the country. The adoption of evidence-based 
and people-centred approaches and the engagement with civil society organisations must 
remain as essential features of Portugal’s HIV health policy.   
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